EMI Holding 10-Q 20 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	20-May-15
Document And Entity Information
Entity Registrant Name	EMMAUS LIFE SCIENCES, INC.
Entity Central Index Key	1420031
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		28,108,013
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$328,359	$556,318
Accounts receivable	14,963	42,734
Inventories, net	267,888	250,413
Marketable securities	53,754	79,236
Marketable securities, pledged to creditor	226,865
Prepaid expenses and other current assets	109,994	129,554
Total current assets	1,001,823	1,058,255
PROPERTY AND EQUIPMENT, Net	68,443	72,391
OTHER ASSETS
Marketable securities, pledged to creditor		334,410
Intangibles, net	839,286	892,857
Deposits	297,552	306,379
Total other assets	1,136,838	1,533,646
Total Assets	2,207,104	2,664,292
CURRENT LIABILITIES
Accounts payable and accrued expenses	3,227,478	2,601,420
Due to related party	394,446	394,446
Notes payable, net	2,957,350	1,643,615
Notes payable to related parties, net	1,190,199	825,562
Convertible notes payable, net	3,138,015	3,456,959
Convertible notes payable to related parties, net	373,000	373,000
Total current liabilities	11,280,488	9,295,002
LONG-TERM LIABILITIES
Deferred rent	48,714	3,729
Liability classified warrants	3,020,000	3,206,000
Warrant derivative liabilities	6,138,000	6,520,000
Notes payable, net		833,335
Notes payable to related parties, net		133,333
Convertible notes payable, net	3,635,761	3,651,555
Convertible notes payable to related parties, net	200,000	200,000
Total long-term liabilities	13,042,475	14,547,952
Total Liabilities	24,322,963	23,842,954
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock - par value $0.001 per share, 20,000,000 shares authorized, none issued and outstanding
Common stock - par value $0.001 per share, 100,000,000 shares authorized, 30,606,335 and 30,511,573 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	30,607	30,512
Additional paid-in capital	53,216,812	50,417,503
Accumulated other comprehensive loss	-326,126	-194,015
Accumulated deficit	-75,037,152	-71,432,662
Total Stockholders' Deficit	-22,115,859	-21,178,662
Total Liabilities & Stockholders' Deficit	$2,207,104	$2,664,292

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Principal Outstanding, Current
Preferred stock, par (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,606,335	30,511,573
Common stock, shares outstanding	30,606,335	30,511,573

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES, Net	$96,759	$84,689
COST OF GOODS SOLD	49,990	46,901
GROSS PROFIT	46,769	37,788
OPERATING EXPENSES
Research and development	244,118	605,040
Selling	157,186	125,931
General and administrative	3,214,796	2,985,914
Operating Expenses	3,616,100	3,716,885
LOSS FROM OPERATIONS	-3,569,331	-3,679,097
OTHER INCOME (EXPENSE)
Change in fair value of liability classified warrants	186,000	-2,883,000
Change in fair value of warrant derivative liabilities	382,000
Interest and other income (loss)	43,538	-18,405
Interest expense	-644,497	-417,361
Nonoperating Income Expense	-32,959	-3,318,766
LOSS BEFORE INCOME TAXES	-3,602,290	-6,997,863
INCOME TAXES	2,200	2,500
NET LOSS	-3,604,490	-7,000,363
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized holding loss on securities available-for-sale	-133,026	-323,828
Unrealized foreign translation	915	886
COMPREHENSIVE LOSS	($3,736,601)	($7,323,305)
NET LOSS PER COMMON SHARE (in dollars per share)	($0.12)	($0.24)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (in shares)	30,581,171	29,228,306

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2014	$30,512	$50,417,503	($194,015)	($71,432,662)	($21,178,662)
Balance, beginning, shares at Dec. 31, 2014	30,511,573
Warrants issued in conjunction with convertible note		220,071			220,071
Proceeds from exercise of warrants	95	102,790			102,885
Proceeds from exercise of warrants, shares	94,762
Beneficial conversion feature related to convertible and promissory notes payable		835,204			835,204
Share-based compensation		1,641,244			1,641,244
Unrealized gain (loss) on marketable securities net of tax			-133,026		-133,026
Foreign currency translation effect			915		915
Net loss				-3,604,490	-3,604,490
Balance, ending at Mar. 31, 2015	$30,607	$53,216,812	($326,126)	($75,037,152)	($22,115,859)
Balance, ending, shares at Mar. 31, 2015	30,606,335

CONSOLIDATED_STATEMENT_OF_CASH

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($3,604,490)	($7,000,363)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	59,094	57,708
Interest expense accrued from discount of convertible notes	339,006	132,129
Share-based compensation	1,641,244	1,607,708
Change in fair value of liability classified warrants	-186,000	2,883,000
Change in fair value of warrant derivative liabilities	-382,000
Net changes in operating assets and liabilities
Accounts receivable	27,918	8,286
Inventory	-16,823	-11,711
Prepaid expenses and other current assets	21,283	46,967
Deposits	9,196	-6,104
Accounts payable and accrued expenses	818,168	110,366
Deferred rent	44,957
Net cash flows used in operating activities	-1,228,447	-2,172,014
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	-1,467	-21,035
Net cash flows used in investing activities	-1,467	-21,035
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable issued	698,783	48,832
Proceeds from convertible notes payable issued	200,000	38,831
Proceeds from exercise of warrants	102,885
Net cash flows from financing activities	1,001,668	87,663
Effect of exchange rate changes on cash	287	1,599
Net decrease in cash and cash equivalents	-227,959	-2,103,787
Cash and cash equivalents, beginning of period	556,318	3,638,600
Cash and cash equivalents, end of period	328,359	1,534,813
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid	62,240	48,713
Income taxes paid	$2,200	$2,500

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated interim financial statements of Emmaus Life Sciences, Inc. and subsidiaries (the “Company” or “Emmaus”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the basis that the Company will continue as a going concern. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated. The Company’s unaudited condensed consolidated interim financial statements contain adjustments, including normal recurring accruals necessary to present fairly the Company’s consolidated financial position, results of operations, comprehensive income (loss) and cash flows. Due to the uncertainty of the Company’s ability to meet its current operating and capital expenses, there is substantial doubt about the Company’s ability to continue as a going concern, as the continuation and expansion of its business is dependent upon obtaining further financing, successful and sufficient market acceptance of its products, and finally, achieving a profitable level of operations. The condensed consolidated interim financial statements do not include any adjustments that might result from the outcome of these uncertainties.  The accompanying condensed consolidated interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed on March 31, 2015 (“Annual Report”).  Interim results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2015.
	The preparation of the condensed consolidated financial statements requires the use of management estimates. Actual results could differ materially from those estimates.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Refer to the Company’s Annual Report for a summary of significant accounting policies.  There have been no material changes to our significant accounting policies during the three months ended March 31, 2015.  Below are disclosures of certain interim balances, transactions, and significant assumptions used in computing fair value as of and for the three months ended March 31, 2015 and comparative amounts from the prior fiscal periods:
	Immaterial corrections of prior year amounts — During the preparation of its condensed consolidated financial statements for the three months ended March 31, 2015, the Company identified the following immaterial error in its consolidated financial statements as of and for the years ended December 31, 2014 and 2013, the interim periods of September 30, 2013 and the interim periods of 2014. This immaterial error has been corrected in the accompanying condensed consolidated financial statements.
	On September 11, 2013, the Company issued an aggregate of 3,020,501 units at a price of $2.50 per unit (the “Private Placement”). Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock. In addition, the Company issued 300,000 common stock purchase warrants as compensation to a broker related to the Private Placement. These warrants had similar rights and features to the other warrants issued in the Private Placement. At the time of issuance on September 11, 2013, the Company did not record the 300,000 common stock purchase warrants at their respective fair value as additional transaction costs. The 300,000 common stock purchase warrants had an initial fair value of $681,000 as of September 11, 2013 of which $62,000 should have been allocated to additional paid in capital and $619,000 allocated to transaction costs in the quarter ended September, 30, 2013, consistent with the relative allocation of the other transaction costs of the Private Placement. In addition, the Company did not account for changes in the fair value of these 300,000 warrants in periods subsequent to their issuance. The fair value of the liability classified warrant was $652,000, $589,000, and $879,000 as of September 30, 2013, December 31, 2013 and December 31, 2014. In addition, the change in the fair value of the 300,000 liability classified warrants was $(29,000) in the quarter ended September 30, 2013, $(63,000) in the quarter ended December 31, 2013, $(92,000) in the year-ended December 31, 2013, $260,000 in the quarter ended March 31, 2014 and $290,000 in the year ended December 31, 2014. Adjustments reflecting the above have been included in the condensed consolidated financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the period ending March 31, 2015 and has been reflected in all prior periods displayed.
	Inventories — All of the raw material purchased during the three months ended March 31, 2015 and for the year ended December 31, 2014 was from one vendor.
	Inventory by category	March 31, 2015			December 31, 2014
	Raw materials and components	$	—		$	43,700
	Work-in-process	73,130			27,665
	Finished goods	194,759			179,048
		$	267,888		$	250,413
	Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the three months ended March 31, 2015 and 2014 were $19,263 and $67,147, respectively.
	Marketable securities — The Company’s marketable securities consist of 48,550 shares of CellSeed, Inc. (“CellSeed”) stock which are part of 147,100 shares acquired in January 2009 for 100,028,000 Japanese Yen (equivalent to $1,109,819), at 680 Yen per share. CellSeed’s IPO (Tokyo Stock Exchange symbol 7776) was completed on March 16, 2010. As of March 31, 2015 and December 31, 2014, the closing price per share was 688 Yen ($5.78) and 1,027 Yen ($8.52), respectively.
	As of March 31, 2015, 9,300 shares of CellSeed stock are classified as a current asset, as they are available for sale by the Company. The remaining 39,250 shares of CellSeed stock are pledged to secure a $500,000 convertible note issued to Mitsubishi UFJ Capital III Limited Partnership that is due in March 2016 and are classified as current assets, as marketable securities, pledged to creditor.
	Fair value measurements — The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the three months ended March 31, 2015 and the year ended December 31, 2014:
		Period ended
	Liability Classified Warrants—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	3,206,000		$	6,517,000
	Fair value at issuance date	—			3,523,000
	Settlement of liability associated with warrants exercised	—			(1,752,744		)
	Reclassification to warrant derivative liabilities	—			(7,068,000		)
	Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss	—			(1,770,256		)
	Change in fair value included in the statement of comprehensive loss	(186,000		)	3,757,000
	Balance, end of period	$	3,020,000		$	3,206,000
		Period ended
	Warrant Derivative Liabilities—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	6,520,000		$	—
	Reclassification from liability classified warrants	—			7,068,000
	Change in fair value included in the statement of comprehensive loss	(382,000		)	(548,000		)
	Balance, end of period	$	6,138,000		$	6,520,000
	The initial value of the liability classified warrants as of September 11, 2013, value of warrant derivative liability as of September 11, 2014 and the change in fair value of the liability classified warrants and warrant derivative liability as of March 31, 2015, September 11, 2014, June 10, 2014 (the date of exercise and issuance), and December 31, 2013 were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of March 31, 2015, December 31, 2014, September 11, 2014, June 10, 2014, December 31, 2013 and the initial value as of September 11, 2013 were calculated based on the following assumptions:
		March 31,			December 31,			September 11,			June 10,			December 31,			Initial
		2015			2014			2014			2014			2013			Value
	Stock price	$	4.9		$	4.9		$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1		%	1.38		%	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	66.4		%	71.5		%	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.45			3.7			3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—			—			—
	Number outstanding	3,320,501			3,320,501			3,320,501			3,320,501			3,320,501			3,320,501
	Balance, end of period:
	Liability classified warrants	$	3,020,000		$	3,206,000		$	3,479,000		$	10,679,000		$	6,517,000		$	7,541,000
	Warrant derivative liabilities	$	6,138,000		$	6,520,000		$	7,068,000		$	—		$	—		$	—
	Debt and related party debt — The following table presents the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conversion		Beneficial			Warrants		Exercise			Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued		Price			FMV		Interest Rate
				Interest		Principal					Discount			with					Discount		Including
				Rate		Amount					Amount			Notes					Amount		Discounts
	2014 convertible notes payable	6 mo. ~ 2 years		10	%	$	3,096,266		$3.05 ~ $3.60		$	1,392,387		50,000		$	3.5		$	126,732	28% ~ 100%
	2015 convertible notes payable	Due on demand ~ 2 years		10	%	1,578,452			$3.50 ~ $3.60		835,204			110,417		$	4.9			220,071	46% ~ 109%
	Total					$	4,674,718				$	2,227,591		160,417					$	346,803
	Related party notes are disclosed as separate line items in the Company’s balance sheet presentation.
	Net loss per share — As of March 31, 2015 and 2014, there were 12,838,502 and 14,254,868 shares of potentially dilutive securities outstanding, respectively. As the Company reported a net loss, none of the potentially dilutive securities were included in the calculation of diluted loss per share since their effect would be anti-dilutive for all periods presented.
	Recent accounting pronouncements — In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, instead of as an asset. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity must apply the amendments on a retrospective basis wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the  prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (that is, the debt issuance cost asset and the debt liability).

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 — PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following at:
		March 31, 2015			December 31, 2014
	Equipment	$	161,712		$	160,201
	Leasehold improvements	30,669			30,579
	Furniture and fixtures	74,714			74,683
	Sub total	267,095			265,463
	Less: accumulated depreciation	(198,652		)	(193,072		)
	Total	$	68,443		$	72,391
	During the three months ended March 31, 2015 and 2014, depreciation expense was $5,523 and $4,137, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 — INTANGIBLE ASSETS
	Intangible assets, related to license fees and patent filing costs associated with NutreStore® L-glutamine powder for oral solution as a treatment for SBS and the Company’s exclusive right to manufacture, sell, market and distribute Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (“CAOMECS”) under the Research Agreement and Individual Agreement with CellSeed (see Note 8) consisted of the following at:
		March 31, 2015			December 31, 2014
	License fees and patent filing costs	$	2,250,000		$	2,250,000
	Less: accumulated amortization	(1,410,714		)	(1,357,143		)
	Total	$	839,286		$	892,857
	During the three months ended March 31, 2015 and 2014, amortization expense was $53,571 and $53,572, respectively. As of March 31, 2015 estimated aggregate amortization expense for the next five years is as follows:
	Periods ending December 31,	Amount
	2015	$	160,715
	2016	214,286
	2017	214,286
	2018	214,286
	2019	35,713
	Total	$	839,286

ACCOUNTS_PAYABLE_AND_ACCRUED_E

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 5 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consisted of the following at:
		March 31, 2015		December 31, 2014
	Accounts payable
	Clinical and regulatory expenses	$	202,797	$	266,537
	Legal expenses	191,657		176,691
	Other vendors	1,357,408		774,444
	Subtotal	1,751,862		1,217,672
	Accrued interest payable, related parties	134,380		110,200
	Accrued interest payable	793,014		761,682
	Accrued expenses	256,556		220,200
	Deferred salary	291,666		291,666
	Total accounts payable and accrued expenses	$	3,227,478	$	2,601,420

NOTES_PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 6 — NOTES PAYABLE
	Notes payable consisted of the following at March 31, 2015 and December 31, 2014:
	Year	Interest		Term of Notes		Conv. Price		Principal		Discount		Carrying		Shares	Principal		Discount		Carrying Amount		Shares
	Issued	Rate Range						Outstanding		Amount March		Amount March		Underlying	Outstanding		Amount		December 31, 2014		Underlying
								March 31, 2015		31, 2015		31, 2015		Principal	December 31,		December 31,				Principal
														March 31, 2015	2014		2014				December 31,
																					2014
	Convertible notes payable
	2010	0 ~ 6.0%		5 years		$3.05		$	74,000	$	1,997	$	72,003	24,248	$	74,000	$	3,195	$	70,805	24,248
	2011	10%		5 years		$3.05		500,000		—		500,000		163,809	500,000		—		500,000		163,809
	2013	10%		2 years		$3.30 ~$3.60		1,841,187		6,889		1,834,298		631,094	2,463,299		18,750		2,444,549		834,667
	2014	10%		Due on demand ~ 2 years		$3.05 ~$7.00		4,164,963		725,073		3,439,890		1,016,475	4,939,773		846,613		4,093,160		1,241,241
	2015	10%		Due on demand ~ 2 years		$3.50 ~$7.00		1,778,453		850,868		927,585		479,363	—		—		—		—
								$	8,358,603	$	1,584,827	$	6,773,776	2,314,989	$	7,977,072	$	868,558	$	7,108,514	2,263,965
				Current				$	3,776,083	$	638,068	$	3,138,015	1,221,962	$	3,478,904	$	21,945	$	3,456,959	1,156,050
				Non-current				$	4,582,520	$	946,759	$	3,635,761	1,093,027	$	4,498,168	$	846,613	$	3,651,555	1,107,915
	Convertible notes payable - related party
	2012	10%		Due on demand		$3.30		$	373,000	$	—	$	373,000	124,248	$	373,000	$	—	$	373,000	121,461
	2014	10%		2 years		$7.00		200,000		—		200,000		30,891	200,000			—	200,000		30,187
								$	573,000	$	—	$	573,000	155,139	$	573,000	$	—	$	573,000	151,648
				Current				$	373,000	$	—	$	373,000	124,248	$	373,000	$	—	$	373,000	121,461
				Non-current				$	200,000	$	—	$	200,000	30,891	$	200,000	$	—	$	200,000	30,187
	Notes payable
	2013	2% ~ 10%		Due on demand ~ 2 years		NA		$	1,040,000	$	—	$	1,040,000	—	$	1,030,000	$	—	$	1,030,000	—
	2014	11%		Due on demand ~ 2 years		NA		1,446,950		—		1,446,950		—	1,446,950		—		1,446,950		—
	2015	11%		Due on demand ~ 2 years		NA		470,400		—		470,400		—	—		—		—		—
								$	2,957,350	$	—	$	2,957,350	—	$	2,476,950	$	—	$	2,476,950	—
				Current				$	2,957,350	$	—	$	2,957,350	—	$	1,643,615	$	—	$	1,643,615	—
				Non-current				$	—	$	—	$	—	—	$	833,335	$	—	$	833,335	—
	Notes payable - related party
	2012	8% ~ 10%		Due on demand		NA		$	656,730	$	—	$	656,730	—	$	656,730	$	—	$	656,730	—
	2013	8%		Due on demand		NA		50,000		—		50,000		—	50,000		—		50,000		—
	2014	11%		Due on demand ~ 2 years		NA		240,308		—		240,308		—	252,165		—		252,165		—
	2015	10% ~ 11%		Due on demand ~ 2 years		NA		243,161		—		243,161		—	—		—		—		—
								$	1,190,199	$	—	$	1,190,199	—	$	958,895	$	—	$	958,895	—
				Current				$	1,190,199	$	—	$	1,190,199	—	$	825,562	$	—	$	825,562	—
				Non-current				$	—	$	—	$	—	—	$	133,333	$	—	$	133,333	—
				Grand Total				$	13,079,152	$	1,584,827	$	11,494,325	2,470,128	$	11,985,917	$	868,558	$	11,117,359	2,415,613
	The average stated interest rate of notes payable as of March 31, 2015 and December 31, 2014 was 10%. The average effective interest rate of notes payable as of March 31, 2015 and December 31, 2014 was 21% and 23%, respectively, after giving effect to discounts relating to beneficial conversion features and the fair value of warrants issued in connection with these notes. The notes payable and convertible notes payable do not have restrictive financial covenants or acceleration clauses associated with a material adverse change event. The holders of the convertible notes have the option to convert their notes into the Company’s common stock at the stated conversion price during the term of their convertible notes. Conversion prices on these convertible notes payable range from $3.05 to $3.60 per share. Certain notes with a $7.00 stated conversion price in the second year of their two year term are subject to automatic conversion into shares of our common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering. All due on demand notes are treated as current liabilities.
	Contractual principal payments due on notes payable are as follows:
	Year Ending	at March 31, 2015
	2015	$	6,466,386
	2016	5,787,192
	2017	825,574
	Total	$	13,079,152
	The Company estimated the total fair value of any beneficial conversion feature and accompanying warrants in allocating the debt proceeds. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares issuable under the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of the Company’s common stock as of the date of issuance (see Note 2). The fair value of the warrants issued in conjunction with notes was determined using the Black Scholes Merton option pricing model with the following inputs for the periods ended:
		March 31, 2015			December 31, 2014
	Stock price	$	4.9		$	4.9
	Exercise price	$	4.9		$	3.5
	Term	5 years			5 years
	Risk-free interest rate	1.57		%	1.66		%
	Expected dividend yield	—			—
	Expected volatility	67.3		%	70.1		%
	In situations where the debt included both a beneficial conversion feature and a warrant, the proceeds were allocated to the warrants and beneficial conversion feature based on the pro-rata fair value.

STOCKHOLDERS_DEFICIT

STOCKHOLDERS' DEFICIT	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 7 — STOCKHOLDERS’ DEFICIT
	Private placement — On September 11, 2013, the Company issued an aggregate of 3,020,501 units at a price of $2.50 per unit. Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock. The aggregate purchase price for the units was $7,551,253.  In addition, 300,000 warrants for the purchase of a share of common stock were issued to a broker under the same terms as the Private Placement transaction (“Broker Warrants”).
	The warrants issued in the Private Placement and the Broker Warrants entitle the holders thereof to purchase, at any time on or prior to September 11, 2018, shares of common stock of the Company at an exercise price of $3.50 per share. The warrants contain non-standard anti-dilution protection and, consequently, are being accounted for as liabilities, were originally recorded at fair value, and are adjusted to fair market value each reporting period. Because the shares of common stock underlying the Private Placement warrants and Broker Warrants were not effectively registered for resale by September 11, 2014, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The shares have not been registered for resale as of March 31, 2015. The availability to warrant holders of the cashless exercise feature as of September 11, 2014 caused the then outstanding 2,225,036 Private Placement warrants and Broker Warrants with fair value of $7,068,000 to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. As of March 31, 2015, the fair value of these 2,225,036 Private Placement warrants and Broker Warrants derivative liabilities was $6,138,000 (see Note 2). For further details regarding registration rights associated with warrants, see the Registration Rights section below in this Footnote.
	Stock warrants —During the three months ended March 31, 2015, in connection with the issuance of a convertible notes, the Company issued five-year warrants to purchase an aggregate of 110,417 shares of common stock of the Company at an exercise price of $4.90 per share.
	Warrant exercises and issuance— During the three months ended March 31, 2015, the Company issued 94,762 shares of common stock upon the exercise of warrants at exercise prices ranging from $1.00 to $3.05 per share, including 22,344 warrants exercised on a cashless basis.
	On June 10, 2014, certain warrant holders exercised 1,095,465 warrants issued in the Private Placement for the exercise price of $3.50 per share, resulting in the Company receiving aggregate exercise proceeds of $3.8 million and issuing 1,095,465 shares of common stock. Prior to exercise, these Private Placement warrants were accounted for at fair value as liability classified warrants. As of June 10, 2014, immediately prior to exercise, the carrying value of these Private Placement warrants was reduced to their fair value immediately prior to exercise of $1.8 million, representing their intrinsic value, with this adjusted carrying value of $1.8 million being transferred to additional paid in capital. Also on June 10, 2014, based on an offer made to holders of Private Placement warrants in connection with such exercises, the Company issued an aggregate of 1,095,465 replacement warrants to holders exercising Private Placement warrants, which replacement warrants have terms that are generally the same as the exercised warrants, including an expiration date of September 11, 2018 and an exercise price of $3.50 per share. The replacement warrants are treated for accounting purposes as liability classified warrants, and their issuance gave rise to a $3.5 million warrant exercise inducement expense based on their fair value as of issuance as determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. If the shares of common stock underlying the replacement warrants are not effectively registered for resale by June 10, 2015, the warrant holders have an option to exercise the replacement warrants using a cashless exercise feature. For more details regarding registration rights associated with the replacement warrants, see “Registration Rights” below.
	A summary of outstanding warrants as of March 31, 2015 and December 31, 2014 is presented below.
		Three months ended		Year ended
		March 31, 2015		December 31, 2014
	Warrants outstanding, beginning of period	5,101,450		6,279,296
	Granted	110,417		1,145,465
	Exercised	(94,762	)	(1,254,621	)
	Cancelled, forfeited or expired	(429,526	)	(1,068,690	)
	Warrants outstanding, end of period	4,687,579		5,101,450
	A summary of outstanding warrants by year issued and exercise price as of March 31, 2015 is presented below.
		Outstanding						Exercisable
	Exercise Price	Number of		Weighted		Weighted		Total		Weighted
		Warrants Issued		Average		Average				Average
				Remaining		Exercise Price				Exercise Price
				Contractual Life
				(Years)
	Balance 2012
	$2.50	1,000,000		0.41		$	2.5	1,000,000		$	2.5
	$3.05	156,661		0.5		$	3.05	156,661		$	3.05
	2012 total	1,156,661						1,156,661
	During 2013
	$3.30	50,000		3.09		$	3.3	50,000		$	3.3
	$3.50	2,225,036		3.45		$	3.5	2,225,036		$	3.5
	2013 total	2,275,036						2,275,036
	During 2014
	$3.50	1,145,465		3.48		$	3.5	1,145,465		$	3.5
	2014 total	1,145,465						1,145,465
	During 2015
	$4.90	110,417		4.93		$	4.9	110,417		$	4.9
	Total	4,687,579						4,687,579
	Stock options — During the three months ended March 31, 2015, no options were granted by the Company’s Board of Directors. During the year ended December 31, 2014, the Company’s Board of Directors granted 840,000 options to its directors, employees and consultants. During the three months ended March 31, 2014, 340,000 options that were approved by the Company’s Board of Directors in April 2012 were deemed issued. The aggregate fair value of these tranches of options, including options granted or deemed issued in 2014 was approximately $3.0 million. As of March 31, 2015, there were 5,669,000 options outstanding under the Emmaus Life Sciences, Inc. 2011 Stock Incentive Plan and 11,795 options outstanding that were issued under the prior Company plan.
	A summary of outstanding options as of March 31, 2015 is presented below.
		Prior Plan					March 31, 2015				December 31, 2014
		Number		Weighted-			Number of	Weighted			Number of		Weighted-
		of		Average			Options	Average			Options		Average
		Options		Exercise				Exercise					Exercise
				Price				Price					Price
	Options outstanding, beginning of period	11,795		$	3.05		5,669,000	$	3.68		4,504,000		$	3.58
	Granted or deemed issued	—		—			—	—			1,180,000		$	4.06
	Exercised	—		—			—	—			—		—
	Cancelled, forfeited and expired	—		—			—	—			(15,000	)	$	3.6
	Options outstanding, end of period	11,795		$	3.05		5,669,000	$	3.68		5,669,000		$	3.68
	Options exercisable, end of period	11,795		$	3.05		3,461,917	$	3.57		2,855,251		$	3.55
	Options available for future grant, end of period	—					3,331,000				3,331,000
	The weighted average grant-date fair value of options granted or deemed issued during the three months ended March 31, 2014 was $2.19. The weighted average grant-date fair value of common shares underlying stock options granted or deemed issued during the three months ended March 31, 2014 was $3.60.
	During the three months ended March 31, 2015 and 2014, the Company recognized $1.6 million and $1.6 million, respectively of share-based compensation cost arising from stock option grants. As of March 31, 2015, there was $4.5 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the 2011 Stock Incentive Plan. That cost is expected to be recognized over the weighted average remaining period of 1.3 years.
	Registration rights — Pursuant to the Subscription Agreements relating to the Private Placement and certain warrants, the Company agreed to use its commercially reasonable best efforts to have on file with the SEC, by September 11, 2014 and at the Company’s sole expense, a registration statement to permit the public resale of 4,115,966 shares of the Company’s common stock and 3,320,501 shares of common stock underlying warrants (collectively, the “Registerable Securities”). In the event such registration statement includes securities to be offered and sold by the Company in a fully underwritten primary public offering pursuant to an effective registration under the Securities Act, and the Company is advised in good faith by any managing underwriter of securities being offered pursuant to such registration statement that the number of Registrable Securities proposed to be sold in such offering is greater than the number of such securities which can be included in such offering without materially adversely affecting such offering, the Company will include in such registration the following securities in the following order of priority: (i) any securities the Company proposes to sell, and (ii) the Registrable Securities, with any reductions in the number of Registrable Securities actually included in such registration to be allocated on a pro rata basis among the holders thereof. The registration rights described above apply until all Registerable Securities have been sold pursuant to Rule 144 under the Securities Act or may be sold without registration in reliance on Rule 144 under the Securities Act without limitation as to volume and without the requirement of any notice filing.
	If the shares of common stock underlying warrants to purchase 2,225,036 shares are not registered for resale at the time of exercise or if the shares of common stock underlying warrants to purchase 1,095,465 shares are not registered for resale at the time of exercise on or after June 10, 2015, and in each such case the registration rights described above then apply with respect to the holder of such warrants, such holder may exercise such warrants on a cashless basis. In such a cashless exercise of all the shares covered by the warrant, the warrant holder would receive a number of shares equal to the quotient of (i) the difference between the fair market value of the common stock, as defined, and the $3.50 exercise price, as adjusted, multiplied by the number of shares exercisable under the warrant, divided by (ii) the fair market value of the common stock, as defined. As of March 31, 2015, based on a fair market value of a share of the Company’s common stock of $4.90 and 2,225,036 warrants issued and outstanding and eligible for cashless exercise, the maximum number of shares the Company would be required to issue, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, is 635,725 shares. If the fair market value of a share of the Company’s common stock were to increase by $1.00 from $4.90 to $5.90, the maximum number of shares the Company would be required to issue, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, would increase to 905,099 shares as of March 31, 2015. The maximum number of shares issuable under cashless exercises, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, would increase to 948,715 on June 10, 2015 based on a fair market value of a share of our common stock of $4.90 and 3,320,501 warrants issued and outstanding and eligible for cashless exercise. If the fair market value of a share of the Company’s common stock were to increase by $1.00 from $4.90 to $5.90, the maximum number of shares the Company would be required to issue, if the warrant holders elected to exercise the cashless exercise feature with respect to all then eligible warrants, would increase to 1,350,712 shares as of June 10, 2015.
	The Company has not yet filed a registration statement with respect to the resale of the Registrable Securities because doing so is not feasible prior to the completion by the Company of its initial public offering. As previously reported, the Company has filed a draft registration statement with the SEC with respect to its initial public offering. The Company believes that it has used commercially reasonable efforts to pursue an initial public offering and, accordingly, considers itself to be in compliance with its registration rights obligations notwithstanding that it has not filed a registration statement with respect to the resale of the Registrable Securities and the deadline for doing so has passed without extension.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 — COMMITMENTS AND CONTINGENCIES
	Distribution contract — Cardinal Health Specialty Pharmacy Services has been contracted to distribute NutreStore to other wholesale distributors and some independent pharmacies since April 2008. For these services, the Company pays a monthly commercialization management fee of $5,000.
	Operating leases — The Company leases its office space under operating leases with unrelated entities. The rent expense during the three months ended March 31, 2015 and 2014 amounted to $118,192 and $46,094, respectively.
	Future minimum lease payments under the agreements are as follows:
	Year	Amount
	2015	$	308,601
	2016	490,140
	2017	467,811
	2018	481,845
	2019	123,766
		$	1,872,163
	Licensing agreement — In April 2011, the Company entered into a Research Agreement and an Individual Agreement with CellSeed and, in August 2011, entered into an addendum to the Research Agreement. Pursuant to the Individual Agreement, CellSeed granted the Company the exclusive right to manufacture, sell, market and distribute Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (“CAOMECS”) for the cornea in the United States and agreed to disclose to the Company its accumulated information package for the joint development of CAOMECS. Under the Individual Agreement, the Company agreed to pay CellSeed $1.5 million, which it paid in February 2012. The technology acquired under the Individual Agreement is being used to support an ongoing research and development project and management believes the technology has alternative future uses in other future development initiatives.
	Pursuant to the Research Agreement, the Company and CellSeed formed a relationship regarding the future research and development of cell sheet engineering regenerative medicine products. Under the Research Agreement, as supplemented by the addendum, the Company agreed to pay CellSeed $8.5 million within 30 days after the completion of all of the following: (i) the execution of the Research Agreement; (ii) the execution of the Individual Agreement; and (iii) CellSeed’s delivery of the accumulated information package, as defined in the Research Agreement, to the Company and the Company providing written confirmation of its acceptance of the complete Package, which has not yet been completed as of March 31, 2015.
	CellSeed may terminate these agreements with the Company if the Company is unable to make timely payments required under the agreements. At the time the Company entered into the agreements with CellSeed, it left for further negotiation provisions covering how the Company and CellSeed will share any financial results of commercializing any cell sheet engineering regenerative medicine products that it is seeking to develop in collaboration with CellSeed. If the Company is not able to successfully negotiate these terms, its current development and commercialization plans with respect to any of these products would be materially adversely affected.

AMOUNTS_RECLASSIFIED_OUT_OF_AC

AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME	3 Months Ended
	Mar. 31, 2015
Amounts Reclassified Out Of Accumulated Other Comprehensive Income
AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME	NOTE 9 — AMOUNTS RECLASSIFIED OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME
	During the three months ended March 31, 2015 and 2014, there were no amounts reclassified from accumulated other comprehensive income.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 — RELATED PARTY TRANSACTIONS
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of March 31, 2015.
	Class	Lender	Annual		Date of	Term of	Principal				Highest			Amount of				Amount of			Conv.		Shares
			Interest		Loan	Loan	Amount				Principal			Principal				Interest			Rate		Underlying
			Rate				Outstanding				Outstanding			Repaid				Paid					Principal at
							at																March 31,
							March 31,																2015
							2015
	Current, Promissory note payable to related parties:
		Hope Hospice (1)	8	%	1/17/12	Due on demand	$		200,000		$		200,000	$		—		$		—	$	—	—
		Hope Hospice (1)	8	%	6/14/12	Due on demand	200,000				200,000			—				—			—		—
		Hope Hospice (1)	8	%	6/21/12	Due on demand	100,000				100,000			—				—			—		—
		Yutaka Niihara (2)(4)	10	%	12/5/12	Due on demand	156,730				1,213,700			1,056,970				—			—		—
		Hope Hospice (1)	8	%	2/11/13	Due on demand	50,000				50,000			—				—			—		—
		Lan T. Tran (2)	11	%	2/10/14	2 years(3)	106,976				106,976			—				—			—		—
		Hideki & Eiko Uehara (5)	11	%	2/15/14	2 years	133,333				133,333			—				—			—		—
		Hope Hospice (1)	10	%	1/7/15	2 years(3)	100,000				100,000			—				—			—		—
		James Lee (5)	10	%	1/26/15	2 years(3)	50,000				50,000			—				—			—		—
		Yutaka Niihara (2)(4)	10	%	1/29/15	2 years(3)	20,000				20,000			—				—			—		—
		Hope Hospice (1)	10	%	1/29/15	2 years(3)	30,000				30,000			—				—			—		—
		Lan T. Tran (2)	10	%	2/9/15	2 years(3)	10,000				10,000			—				—			—		—
		Charles Stark (2)	10	%	2/10/15	2 years(3)	10,000				10,000			—				—			—		—
		IRA Service Trust Co. FBO Peter B. Ludlum (2)	10	%	2/20/15	2 years(3)	10,000				10,000			—				—			—		—
		Cuc T. Tran (5)	11	%	3/5/15	1 year	13,161				13,161			—				—			—		—
						Sub total	$		1,190,199		$		2,247,170	$		1,056,970		$		—	$	—	—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki (2)	10	%	6/29/12	Due on demand	$		373,000		$		388,800	$		15,800		$		—	$	3.3	124,248
						Sub total	$		373,000		$		388,800	$		15,800		$		—	$	—	124,248
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow (4)	10	%	6/6/14	2 years	$		100,000		$		100,000	$		—		$		—	$	7	15,455
		Richard S. Pechter (5)	10	%	6/11/14	2 years	100,000				100,000			—				—			$	7	15,436
						Sub total	$		200,000		$		200,000	$		—		$		—	$	—	30,891
						Total	$		1,763,199		$		2,835,970	$		1,072,770		$		—	$	—	155,139
	(1) Dr. Niihara is the CEO of Hope Hospice.
	(2) Officer
	(3) Due on Demand
	(4) Director
	(5) Family of Officer/Director
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of December 31, 2014.
	Class	Lender	Annual		Date of	Term of	Principal			Highest			Amount of		Amount of				Conv.		Shares
			Interest		Loan	Loan	Amount			Principal			Principal		Interest				Rate		Underlying
			Rate				Outstanding			Outstanding			Repaid		Paid						Principal at
							at														December 31,
							December 31,														2014
							2014
	Current, Promissory note payable to related parties:
		Hope Hospice(1)	8	%	1/17/12	Due on demand	$	200,000		$		200,000	$	—	$		16,000		$	—	—
		Hope Hospice(1)	8	%	6/14/12	Due on demand	200,000			200,000			—		20,000				—		—
		Hope Hospice(1)	8	%	6/21/12	Due on demand	100,000			100,000			—		10,000				—		—
		Yutaka Niihara(2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700			1,056,970		60,851				—		—
		Hope Hospice(1)	8	%	2/11/13	Due on demand	50,000			50,000			—		4,000				—		—
		Lan T. Tran(2)	11	%	2/10/14	2 years(3)	106,976			106,976			—		—				—		—
		Cuc T. Tran(5)	11	%	3/5/14	1 year	11,856			11,856			—		—				—		—
						Sub total	$	825,562		$		1,882,532	$	1,056,970	$		110,851		$	—	—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki(2)	10	%	6/29/12	Due on demand	$	373,000		$		388,800	$	15,800	$		67,680		$	3.3	121,461
						Sub total	$	373,000		$		388,800	$	15,800	$		67,680		$	—	121,461
	Long-term, Promissory note payable to related parties:
		Hideki & Eiko Uehara(5)	11	%	2/15/14	2 years	$	133,333		$		133,333	$	—	$		14,697		$	—	—
						Sub total	$	133,333		$		133,333	$	—	$		14,697		$	—	—
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow(4)	10	%	6/6/14	2 years	$	100,000		$		100,000	$	—	$		—		$	7	15,103
		Richard S. Pechter(5)	10	%	6/11/14	2 years	100,000			100,000			—		—				$	7	15,084
						Sub total	$	200,000		$		200,000	$	—	$		—		$	—	30,187
					Total	$	1,531,895		$		2,604,665	$	1,072,770	$		193,228		$	—	151,648
(1) Dr. Niihara is the CEO of Hope Hospice.
(2) Officer
(3) Due on Demand
(4) Director
(5) Family of Officer/Director
Since July 2012, the Company has been engaged in litigation with AFH Advisory, which was the sole stockholder of AFH Acquisition IV immediately prior to its combination with Emmaus Medical pursuant to the Merger in May 2011. In September 2012, AFH Advisory and related parties filed a complaint against the Company in the Superior Court of Delaware. In October 2012, the Company filed counterclaims against the plaintiffs and third-party claims against Amir Heshmatpour. Mr. Heshmatpour is a former officer of AFH Acquisition IV, Inc. (prior to the Merger) and former director of the Company and is the Managing Partner of AFH Advisory. On June 27, 2013, the Superior Court of the State of Delaware issued an order implementing a partial summary judgment in favor of the Company in its litigation against AFH Advisory, Griffin Ventures, Ltd. (‘‘Griffin’’), The Amir & Kathy Heshmatpour Family Foundation (the ‘‘Foundation’’) and Amir Heshmatpour. The order, among other things, (i) stated that a letter of intent previously entered into between the Company and AFH Advisory (the ‘‘Letter of Intent’’) was properly terminated as of July 19, 2012 by the Company, and (ii) ordered the transfer agent for the Company to effect the cancellation of 2,504,249 shares of the Company’s common stock held by AFH Advisory, Griffin and the Foundation. The cancellation of such shares was effected by the Company’s transfer agent on June 28, 2013. The cancellation of such shares was subject to appeal until 30 days after the completion of trial court proceedings. While the partial summary judgment in favor of the Company in this litigation noted above led to the cancellation of 2,504,249 shares of the Company by the transfer agent on June 28, 2013, the Company has continued to present these shares in its financial statements as outstanding until the right of appeal has lapsed and all contingencies have been resolved. The Company’s cause of action for fraud, which was not part of the summary judgment, had not yet been litigated or settled as of March 31, 2015. On May 4, 2015, a settlement was entered with the Superior Court of the State of Delaware dismissing the case with prejudice, thus removing any right to appeal.

GEOGRAPHIC_INFORMATION

GEOGRAPHIC INFORMATION	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION	NOTE 11 — GEOGRAPHIC INFORMATION
	For the three months ended March 31, 2015 and 2014, the Company earned revenue from countries outside of the United States as outlined in the table below:
	Country	Revenues for		% of total revenue for the		Revenues for the		% of total revenue for the
		the three months ended		three months ended		three months ended		three months ended
		March 31, 2015		March 31, 2015		March 31, 2014		March 31, 2014
	Japan	$	42,743	44	%	$	41,778	43	%
	Taiwan	42,613		44	%	27,730		28	%
	The Company did not have any significant currency translation or foreign transaction adjustments during the three months ended March 31, 2015 and 2014.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 — SUBSEQUENT EVENTS
	Subsequent to March 31, 2015, the Company issued the following:
	Notes issued after March 31, 2015	Loan Principal Outstanding		Annual Interest Rate		Term of Notes	Conversion Price
	Convertible note (1)	$	462,993	10	%	2 years	$	3.6
	Convertible note (1)	272,640		10	%	2 years	$	3.5
	Convertible notes (2)	893,343		10	%	2 years	$	4.5
	Promissory note — related party (3)	500,000		10	%	On demand up to 2 years	—
	Promissory note	1,500,000		11	%	On demand up to 2 years	—
		$	3,628,976
	(1)         Refinance of prior note
	(2)         Includes mandatory conversion at the time of an initial public offering at a conversion price equal to 80% of the initial public offering price.
	(3)         This is a related party loan from Dr. Niihara, an officer and director of the Company.
	Subsequent to March 31, 2015, the Company settled an outstanding legal case. Since July 2012 the Company has been engaged in litigation with AFH Advisory, which was the sole stockholder of AFH Acquisition IV immediately prior to its combination with Emmaus Medical pursuant to the Merger in May 2011. On June 27, 2013, the Superior Court of the State of Delaware issued an order implementing a partial summary judgment in favor of the Company which led to the cancellation of 2,504,249 shares of the Company held by AFH and related parties. The Company has continued to present these shares in its financial statements as outstanding until the right of appeal has lapsed and all contingencies have been resolved. The Company’s cause of action for fraud, which was not part of the summary judgment, had not yet been litigated or settled as of March 31, 2015. On May 4, 2015 a settlement was entered with the Superior Court of the State of Delaware dismissing the case with prejudice, thus removing any right to appeal.
	On April 28, 2015, Dr. Yutaka Niihara, the Company’s former President and Chief Executive Officer and current Chairman of the Board and Chief Scientific Officer, filed a complaint (the “Complaint”) in the Court of Chancery of the State of Delaware (the “Court”) under Section 225 of the Delaware General Corporation Law against Tracey Doi, Henry A. McKinnell, Jr., Akiko M. Miyashita, Phillip M. Satow and Mayuran Sriskandarajah, each of whom was a member of the Board as of April 24, 2015 (together with Dr. Niihara, the “Incumbent Directors”), Sarissa Capital Management L.P. (“Sarissa”) and T.R. Winston & Company, LLC (“TRW”), as defendants, and the Company as nominal defendant. On April 29, 2015, following their resignations from our Board, Tracey Doi and Akiko M. Miyashita were dismissed from the action. The Complaint requests that the Court issue an order declaring, among other things, that:
	·                  Dr. Niihara validly delivered stockholder consents to the Company to effect certain amendments to the Company’s By-laws and to elect certain additional individuals to the Company’s Board of Directors, and that such stockholder consents are effective;
	·                  the Company’s By-laws were validly amended as provided in the stockholder consents;
	·                  Blair A. Contratto, S. Steve Lee, Willis C. Lee, Matsuhara Osato, M.D., Lan T. Tran, David J. Wohlberg and Ian Zwicker were validly elected as directors of the Company;
	·                  any actions taken by the Incumbent Directors since April 24, 2015 are invalid and void; and
	·                  the actions purportedly taken by written consent were not prohibited by the terms of the Agreement, dated as of September 11, 2013, among the Company, Dr. Niihara, Sarissa and TRW.
	Along with the Complaint, Dr. Niihara filed a motion for order maintaining the status quo and a motion for expedited proceedings.
	The Company does not expect the impact of this complaint to affect its financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Inventories	Inventories — All of the raw material purchased during the three months ended March 31, 2015 and for the year ended December 31, 2014 was from one vendor.
	Inventory by category	March 31, 2015			December 31, 2014
	Raw materials and components	$	—		$	43,700
	Work-in-process	73,130			27,665
	Finished goods	194,759			179,048
		$	267,888		$	250,413
Advertising cost	Advertising cost — Advertising costs are expensed as incurred. Advertising costs for the three months ended March 31, 2015 and 2014 were $19,263 and $67,147, respectively.
Marketable securities	Marketable securities — The Company’s marketable securities consist of 48,550 shares of CellSeed, Inc. (“CellSeed”) stock which are part of 147,100 shares acquired in January 2009 for 100,028,000 Japanese Yen (equivalent to $1,109,819), at 680 Yen per share. CellSeed’s IPO (Tokyo Stock Exchange symbol 7776) was completed on March 16, 2010. As of March 31, 2015 and December 31, 2014, the closing price per share was 688 Yen ($5.78) and 1,027 Yen ($8.52), respectively.
	As of March 31, 2015, 9,300 shares of CellSeed stock are classified as a current asset, as they are available for sale by the Company. The remaining 39,250 shares of CellSeed stock are pledged to secure a $500,000 convertible note issued to Mitsubishi UFJ Capital III Limited Partnership that is due in March 2016 and are classified as current assets, as marketable securities, pledged to creditor.
Fair value measurements	Fair value measurements — The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the three months ended March 31, 2015 and the year ended December 31, 2014:
		Period ended
	Liability Classified Warrants—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	3,206,000		$	6,517,000
	Fair value at issuance date	—			3,523,000
	Settlement of liability associated with warrants exercised	—			(1,752,744		)
	Reclassification to warrant derivative liabilities	—			(7,068,000		)
	Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss	—			(1,770,256		)
	Change in fair value included in the statement of comprehensive loss	(186,000		)	3,757,000
	Balance, end of period	$	3,020,000		$	3,206,000
		Period ended
	Warrant Derivative Liabilities—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	6,520,000		$	—
	Reclassification from liability classified warrants	—			7,068,000
	Change in fair value included in the statement of comprehensive loss	(382,000		)	(548,000		)
	Balance, end of period	$	6,138,000		$	6,520,000
	The initial value of the liability classified warrants as of September 11, 2013, value of warrant derivative liability as of September 11, 2014 and the change in fair value of the liability classified warrants and warrant derivative liability as of March 31, 2015, September 11, 2014, June 10, 2014 (the date of exercise and issuance), and December 31, 2013 were determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models except that the exercise price resets at certain dates in the future. The values as of March 31, 2015, December 31, 2014, September 11, 2014, June 10, 2014, December 31, 2013 and the initial value as of September 11, 2013 were calculated based on the following assumptions:
		March 31,			December 31,			September 11,			June 10,			December 31,			Initial
		2015			2014			2014			2014			2013			Value
	Stock price	$	4.9		$	4.9		$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1		%	1.38		%	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	66.4		%	71.5		%	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.45			3.7			3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—			—			—
	Number outstanding	3,320,501			3,320,501			3,320,501			3,320,501			3,320,501			3,320,501
	Balance, end of period:
	Liability classified warrants	$	3,020,000		$	3,206,000		$	3,479,000		$	10,679,000		$	6,517,000		$	7,541,000
	Warrant derivative liabilities	$	6,138,000		$	6,520,000		$	7,068,000		$	—		$	—		$	—
Debt and Related Party Debt	Debt and Related Party Debt — The following table presents the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conversion		Beneficial			Warrants		Exercise			Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued		Price			FMV		Interest Rate
				Interest		Principal					Discount			with					Discount		Including
				Rate		Amount					Amount			Notes					Amount		Discounts
	2014 convertible notes payable	6 mo. ~ 2 years		10	%	3,096,266			$3.05 ~ $3.60		1,392,387			50,000		$	3.5		$	126,732	28% ~ 100%
	2015 convertible notes payable	Due on demand ~ 2 years		10	%	1,578,452			$3.50 ~ $3.60		835,204			110,417		$	4.9		$	220,071	46% ~ 109%
	Total					$	4,674,718				$	2,227,591		160,417					$	346,803
	Related party notes are disclosed as separate line items in the Company’s balance sheet presentation.
Net loss per share	Net loss per share — As of March 31, 2015 and 2014, there were 12,838,502 and 14,254,868 shares of potentially dilutive securities outstanding, respectively. As the Company reported a net loss, none of the potentially dilutive securities were included in the calculation of diluted loss per share since their effect would be anti-dilutive for all periods presented.
Recent accounting pronouncements	Recent accounting pronouncements — In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts, instead of as an asset. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. The amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity must apply the amendments on a retrospective basis wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the  prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (that is, the debt issuance cost asset and the debt liability).

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of inventory	All of the raw material purchased during the three months ended March 31, 2015 and for the year ended December 31, 2014 was from one vendor.
	Inventory by category	March 31, 2015			December 31, 2014
	Raw materials and components	$	—		$	43,700
	Work-in-process	73,130			27,665
	Finished goods	194,759			179,048
		$	267,888		$	250,413
Schedule of changes in fair value of Level 3 liabilities	The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 inputs during the three months ended March 31, 2015 and the year ended December 31, 2014:
		Period ended
	Liability Classified Warrants—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	3,206,000		$	6,517,000
	Fair value at issuance date	—			3,523,000
	Settlement of liability associated with warrants exercised	—			(1,752,744		)
	Reclassification to warrant derivative liabilities	—			(7,068,000		)
	Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss	—			(1,770,256		)
	Change in fair value included in the statement of comprehensive loss	(186,000		)	3,757,000
	Balance, end of period	$	3,020,000		$	3,206,000
		Period ended
	Warrant Derivative Liabilities—Stock Purchase Warrants	March 31, 2015			December 31, 2014
	Balance, beginning of period	$	6,520,000		$	—
	Reclassification from liability classified warrants	—			7,068,000
	Change in fair value included in the statement of comprehensive loss	(382,000		)	(548,000		)
	Balance, end of period	$	6,138,000		$	6,520,000
Schedule of valuation assumptions for warrants	The values as of March 31, 2015, December 31, 2014, September 11, 2014, June 10, 2014, December 31, 2013 and the initial value as of September 11, 2013 were calculated based on the following assumptions:
		March 31,			December 31,			September 11,			June 10,			December 31,			Initial
		2015			2014			2014			2014			2013			Value
	Stock price	$	4.9		$	4.9		$	5.1		$	5.1		$	3.6		$	3.6
	Risk-free interest rate	1		%	1.38		%	1.43		%	1.32		%	1.75		%	1.72		%
	Expected volatility (peer group)	66.4		%	71.5		%	69.5		%	68.2		%	63.2		%	72.4		%
	Expected life (in years)	3.45			3.7			3.95			4.26			4.7			5
	Expected dividend yield	—			—			—			—			—			—
	Number outstanding	3,320,501			3,320,501			3,320,501			3,320,501			3,320,501			3,320,501
	Balance, end of period:
	Liability classified warrants	$	3,020,000		$	3,206,000		$	3,479,000		$	10,679,000		$	6,517,000		$	7,541,000
	Warrant derivative liabilities	$	6,138,000		$	6,520,000		$	7,068,000		$	—		$	—		$	—
Schedule of convertible notes payable	The following table presents the effective interest rates on the original loan principal amount for loans originated in the respective periods that either had a beneficial conversion interest or an attached warrant:
	Type of Loan	Term of		Stated		Original			Conversion		Beneficial			Warrants		Exercise			Warrant		Effective
		Loan		Annual		Loan			Rate		Conversion			Issued		Price			FMV		Interest Rate
				Interest		Principal					Discount			with					Discount		Including
				Rate		Amount					Amount			Notes					Amount		Discounts
	2014 convertible notes payable	6 mo. ~ 2 years		10	%	3,096,266			$3.05 ~ $3.60		1,392,387			50,000		$	3.5		$	126,732	28% ~ 100%
	2015 convertible notes payable	Due on demand ~ 2 years		10	%	1,578,452			$3.50 ~ $3.60		835,204			110,417		$	4.9		$	220,071	46% ~ 109%
	Total					$	4,674,718				$	2,227,591		160,417					$	346,803

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following at:
		March 31, 2015			December 31, 2014
	Equipment	$	161,712		$	160,201
	Leasehold improvements	30,669			30,579
	Furniture and fixtures	74,714			74,683
	Sub total	267,095			265,463
	Less: accumulated depreciation	(198,652		)	(193,072		)
	Total	$	68,443		$	72,391

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets, related to license fees and patent filing costs associated with NutreStore® L-glutamine powder for oral solution as a treatment for SBS and the Company’s exclusive right to manufacture, sell, market and distribute Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (“CAOMECS”) under the Research Agreement and Individual Agreement with CellSeed (see Note 8) consisted of the following at:
		March 31, 2015			December 31, 2014
	License fees and patent filing costs	$	2,250,000		$	2,250,000
	Less: accumulated amortization	(1,410,714		)	(1,357,143		)
	Total	$	839,286		$	892,857
Schedule of estimated aggregate amortization expense for the next five years	As of March 31, 2015 estimated aggregate amortization expense for the next five years is as follows:
	Periods ending December 31,	Amount
	2015	$	160,715
	2016	214,286
	2017	214,286
	2018	214,286
	2019	35,713
	Total	$	839,286

ACCOUNTS_PAYABLE_AND_ACCRUED_E1

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued expenses	Accounts payable and accrued expenses consisted of the following at:
		March 31, 2015		December 31, 2014
	Accounts payable
	Clinical and regulatory expenses	$	202,797	$	266,537
	Legal expenses	191,657		176,691
	Other vendors	1,357,408		774,444
	Subtotal	1,751,862		1,217,672
	Accrued interest payable, related parties	134,380		110,200
	Accrued interest payable	793,014		761,682
	Accrued expenses	256,556		220,200
	Deferred salary	291,666		291,666
	Total accounts payable and accrued expenses	$	3,227,478	$	2,601,420

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable consisted of the following at March 31, 2015 and December 31, 2014:
	Year	Interest		Term of Notes		Conv. Price		Principal		Discount		Carrying		Shares	Principal		Discount		Carrying Amount		Shares
	Issued	Rate Range						Outstanding		Amount March		Amount March		Underlying	Outstanding		Amount		December 31, 2014		Underlying
								March 31, 2015		31, 2015		31, 2015		Principal	December 31,		December 31,				Principal
														March 31, 2015	2014		2014				December 31,
																					2014
	Convertible notes payable
	2010	0 ~ 6.0%		5 years		$3.05		$	74,000	$	1,997	$	72,003	24,248	$	74,000	$	3,195	$	70,805	24,248
	2011	10%		5 years		$3.05		500,000		—		500,000		163,809	500,000		—		500,000		163,809
	2013	10%		2 years		$3.30 ~$3.60		1,841,187		6,889		1,834,298		631,094	2,463,299		18,750		2,444,549		834,667
	2014	10%		Due on demand ~ 2 years		$3.05 ~$7.00		4,164,963		725,073		3,439,890		1,016,475	4,939,773		846,613		4,093,160		1,241,241
	2015	10%		Due on demand ~ 2 years		$3.50 ~$7.00		1,778,453		850,868		927,585		479,363	—		—		—		—
								$	8,358,603	$	1,584,827	$	6,773,776	2,314,989	$	7,977,072	$	868,558	$	7,108,514	2,263,965
				Current				$	3,776,083	$	638,068	$	3,138,015	1,221,962	$	3,478,904	$	21,945	$	3,456,959	1,156,050
				Non-current				$	4,582,520	$	946,759	$	3,635,761	1,093,027	$	4,498,168	$	846,613	$	3,651,555	1,107,915
	Convertible notes payable - related party
	2012	10%		Due on demand		$3.30		$	373,000	$	—	$	373,000	124,248	$	373,000	$	—	$	373,000	121,461
	2014	10%		2 years		$7.00		200,000		—		200,000		30,891	200,000			—	200,000		30,187
								$	573,000	$	—	$	573,000	155,139	$	573,000	$	—	$	573,000	151,648
				Current				$	373,000	$	—	$	373,000	124,248	$	373,000	$	—	$	373,000	121,461
				Non-current				$	200,000	$	—	$	200,000	30,891	$	200,000	$	—	$	200,000	30,187
	Notes payable
	2013	2% ~ 10%		Due on demand ~ 2 years		NA		$	1,040,000	$	—	$	1,040,000	—	$	1,030,000	$	—	$	1,030,000	—
	2014	11%		Due on demand ~ 2 years		NA		1,446,950		—		1,446,950		—	1,446,950		—		1,446,950		—
	2015	11%		Due on demand ~ 2 years		NA		470,400		—		470,400		—	—		—		—		—
								$	2,957,350	$	—	$	2,957,350	—	$	2,476,950	$	—	$	2,476,950	—
				Current				$	2,957,350	$	—	$	2,957,350	—	$	1,643,615	$	—	$	1,643,615	—
				Non-current				$	—	$	—	$	—	—	$	833,335	$	—	$	833,335	—
	Notes payable - related party
	2012	8% ~ 10%		Due on demand		NA		$	656,730	$	—	$	656,730	—	$	656,730	$	—	$	656,730	—
	2013	8%		Due on demand		NA		50,000		—		50,000		—	50,000		—		50,000		—
	2014	11%		Due on demand ~ 2 years		NA		240,308		—		240,308		—	252,165		—		252,165		—
	2015	10% ~ 11%		Due on demand ~ 2 years		NA		243,161		—		243,161		—	—		—		—		—
								$	1,190,199	$	—	$	1,190,199	—	$	958,895	$	—	$	958,895	—
				Current				$	1,190,199	$	—	$	1,190,199	—	$	825,562	$	—	$	825,562	—
				Non-current				$	—	$	—	$	—	—	$	133,333	$	—	$	133,333	—
				Grand Total				$	13,079,152	$	1,584,827	$	11,494,325	2,470,128	$	11,985,917	$	868,558	$	11,117,359	2,415,613
Schedule of contractual principal payments of loans and notes payable	Contractual principal payments due on notes payable are as follows:
	Year Ending	at March 31, 2015
	2015	$	6,466,386
	2016	5,787,192
	2017	825,574
	Total	$	13,079,152
Schedule of fair value assumptions for warrants issued in conjunction with notes	The fair value of the warrants issued in conjunction with notes was determined using the Black Scholes Merton option pricing model with the following inputs for the periods ended:
		March 31, 2015			December 31, 2014
	Stock price	$	4.9		$	4.9
	Exercise price	$	4.9		$	3.5
	Term	5 years			5 years
	Risk-free interest rate	1.57		%	1.66		%
	Expected dividend yield	—			—
	Expected volatility	67.3		%	70.1		%

STOCKHOLDERS_EQUITY_DEFICIT_Ta

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of outstanding warrants	A summary of outstanding warrants as of March 31, 2015 and December 31, 2014 is presented below.
		Three months ended		Year ended
		March 31, 2015		December 31, 2014
	Warrants outstanding, beginning of period	5,101,450		6,279,296
	Granted	110,417		1,145,465
	Exercised	(94,762	)	(1,254,621	)
	Cancelled, forfeited or expired	(429,526	)	(1,068,690	)
	Warrants outstanding, end of period	4,687,579		5,101,450
Schedule of warrant exercise price	A summary of outstanding warrants by year issued and exercise price as of March 31, 2015 is presented below.
		Outstanding						Exercisable
	Exercise Price	Number of		Weighted		Weighted		Total		Weighted
		Warrants Issued		Average		Average				Average
				Remaining		Exercise Price				Exercise Price
				Contractual Life
				(Years)
	Balance 2012
	$2.50	1,000,000		0.41		$	2.5	1,000,000		$	2.5
	$3.05	156,661		0.5		$	3.05	156,661		$	3.05
	2012 total	1,156,661						1,156,661
	During 2013
	$3.30	50,000		3.09		$	3.3	50,000		$	3.3
	$3.50	2,225,036		3.45		$	3.5	2,225,036		$	3.5
	2013 total	2,275,036						2,275,036
	During 2014
	$3.50	1,145,465		3.48		$	3.5	1,145,465		$	3.5
	2014 total	1,145,465						1,145,465
	During 2015
	$4.90	110,417		4.93		$	4.9	110,417		$	4.9
	Total	4,687,579						4,687,579
Schedule of outstanding options	A summary of outstanding options as of March 31, 2015 is presented below.
		Prior Plan					March 31, 2015				December 31, 2014
		Number		Weighted-			Number of	Weighted			Number of		Weighted-
		of		Average			Options	Average			Options		Average
		Options		Exercise				Exercise					Exercise
				Price				Price					Price
	Options outstanding, beginning of period	11,795		$	3.05		5,669,000	$	3.68		4,504,000		$	3.58
	Granted or deemed issued	—		—			—	—			1,180,000		$	4.06
	Exercised	—		—			—	—			—		—
	Cancelled, forfeited and expired	—		—			—	—			(15,000	)	$	3.6
	Options outstanding, end of period	11,795		$	3.05		5,669,000	$	3.68		5,669,000		$	3.68
	Options exercisable, end of period	11,795		$	3.05		3,461,917	$	3.57		2,855,251		$	3.55
	Options available for future grant, end of period	—					3,331,000				3,331,000

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments	Future minimum lease payments under the agreements are as follows:
	Year	Amount
	2015	$	308,601
	2016	490,140
	2017	467,811
	2018	481,845
	2019	123,766
		$	1,872,163

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of related parties outstanding loans	The following table sets forth information relating to the Company’s loans from related persons outstanding as of March 31, 2015.
	Class	Lender	Annual		Date of	Term of	Principal				Highest			Amount of				Amount of			Conv.		Shares
			Interest		Loan	Loan	Amount				Principal			Principal				Interest			Rate		Underlying
			Rate				Outstanding				Outstanding			Repaid				Paid					Principal at
							at																March 31,
							March 31,																2015
							2015
	Current, Promissory note payable to related parties:
		Hope Hospice (1)	8	%	1/17/12	Due on demand	$		200,000		$		200,000	$		—		$		—	$	—	—
		Hope Hospice (1)	8	%	6/14/12	Due on demand	200,000				200,000			—				—			—		—
		Hope Hospice (1)	8	%	6/21/12	Due on demand	100,000				100,000			—				—			—		—
		Yutaka Niihara (2)(4)	10	%	12/5/12	Due on demand	156,730				1,213,700			1,056,970				—			—		—
		Hope Hospice (1)	8	%	2/11/13	Due on demand	50,000				50,000			—				—			—		—
		Lan T. Tran (2)	11	%	2/10/14	2 years(3)	106,976				106,976			—				—			—		—
		Hideki & Eiko Uehara (5)	11	%	2/15/14	2 years	133,333				133,333			—				—			—		—
		Hope Hospice (1)	10	%	1/7/15	2 years(3)	100,000				100,000			—				—			—		—
		James Lee (5)	10	%	1/26/15	2 years(3)	50,000				50,000			—				—			—		—
		Yutaka Niihara (2)(4)	10	%	1/29/15	2 years(3)	20,000				20,000			—				—			—		—
		Hope Hospice (1)	10	%	1/29/15	2 years(3)	30,000				30,000			—				—			—		—
		Lan T. Tran (2)	10	%	2/9/15	2 years(3)	10,000				10,000			—				—			—		—
		Charles Stark (2)	10	%	2/10/15	2 years(3)	10,000				10,000			—				—			—		—
		IRA Service Trust Co. FBO Peter B. Ludlum (2)	10	%	2/20/15	2 years(3)	10,000				10,000			—				—			—		—
		Cuc T. Tran (5)	11	%	3/5/15	1 year	13,161				13,161			—				—			—		—
						Sub total	$		1,190,199		$		2,247,170	$		1,056,970		$		—	$	—	—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki (2)	10	%	6/29/12	Due on demand	$		373,000		$		388,800	$		15,800		$		—	$	3.3	124,248
						Sub total	$		373,000		$		388,800	$		15,800		$		—	$	—	124,248
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow (4)	10	%	6/6/14	2 years	$		100,000		$		100,000	$		—		$		—	$	7	15,455
		Richard S. Pechter (5)	10	%	6/11/14	2 years	100,000				100,000			—				—			$	7	15,436
						Sub total	$		200,000		$		200,000	$		—		$		—	$	—	30,891
						Total	$		1,763,199		$		2,835,970	$		1,072,770		$		—	$	—	155,139
	(1) Dr. Niihara is the CEO of Hope Hospice.
	(2) Officer
	(3) Due on Demand
	(4) Director
	(5) Family of Officer/Director
	The following table sets forth information relating to the Company’s loans from related persons outstanding as of December 31, 2014.
	Class	Lender	Annual		Date of	Term of	Principal			Highest			Amount of		Amount of				Conv.		Shares
			Interest		Loan	Loan	Amount			Principal			Principal		Interest				Rate		Underlying
			Rate				Outstanding			Outstanding			Repaid		Paid						Principal at
							at														December 31,
							December 31,														2014
							2014
	Current, Promissory note payable to related parties:
		Hope Hospice(1)	8	%	1/17/12	Due on demand	$	200,000		$		200,000	$	—	$		16,000		$	—	—
		Hope Hospice(1)	8	%	6/14/12	Due on demand	200,000			200,000			—		20,000				—		—
		Hope Hospice(1)	8	%	6/21/12	Due on demand	100,000			100,000			—		10,000				—		—
		Yutaka Niihara(2)(4)	10	%	12/5/12	Due on demand	156,730			1,213,700			1,056,970		60,851				—		—
		Hope Hospice(1)	8	%	2/11/13	Due on demand	50,000			50,000			—		4,000				—		—
		Lan T. Tran(2)	11	%	2/10/14	2 years(3)	106,976			106,976			—		—				—		—
		Cuc T. Tran(5)	11	%	3/5/14	1 year	11,856			11,856			—		—				—		—
						Sub total	$	825,562		$		1,882,532	$	1,056,970	$		110,851		$	—	—
	Current, Convertible notes payable to related parties:
		Yasushi Nagasaki(2)	10	%	6/29/12	Due on demand	$	373,000		$		388,800	$	15,800	$		67,680		$	3.3	121,461
						Sub total	$	373,000		$		388,800	$	15,800	$		67,680		$	—	121,461
	Long-term, Promissory note payable to related parties:
		Hideki & Eiko Uehara(5)	11	%	2/15/14	2 years	$	133,333		$		133,333	$	—	$		14,697		$	—	—
						Sub total	$	133,333		$		133,333	$	—	$		14,697		$	—	—
	Long-term, Convertible notes payable to related parties:
		Phillip M. Satow(4)	10	%	6/6/14	2 years	$	100,000		$		100,000	$	—	$		—		$	7	15,103
		Richard S. Pechter(5)	10	%	6/11/14	2 years	100,000			100,000			—		—				$	7	15,084
						Sub total	$	200,000		$		200,000	$	—	$		—		$	—	30,187
						Total	$	1,531,895		$		2,604,665	$	1,072,770	$		193,228		$	—	151,648
(1) Dr. Niihara is the CEO of Hope Hospice.
(2) Officer
(3) Due on Demand
(4) Director
(5) Family of Officer/Director

GEOGRAPHIC_INFORMATION_Tables

GEOGRAPHIC INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of revenue earned from countries outside of the United States	For the three months ended March 31, 2015 and 2014, the Company earned revenue from countries outside of the United States as outlined in the table below:
	Country	Revenues for		% of total revenue for the		Revenues for the		% of total revenue for the
		the three months ended		three months ended		three months ended		three months ended
		March 31, 2015		March 31, 2015		March 31, 2014		March 31, 2014
	Japan	$	42,743	44	%	$	41,778	43	%
	Taiwan	42,613		44	%	27,730		28	%

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Schedule of subsequent events notes payable	Subsequent to March 31, 2015, the Company issued the following:
	Notes issued after March 31, 2015	Loan Principal Outstanding		Annual Interest Rate		Term of Notes	Conversion Price
	Convertible note (1)	$	462,993	10	%	2 years	$	3.6
	Convertible note (1)	272,640		10	%	2 years	$	3.5
	Convertible notes (2)	893,343		10	%	2 years	$	4.5
	Promissory note — related party (3)	500,000		10	%	On demand up to 2 years	—
	Promissory note	1,500,000		11	%	On demand up to 2 years	—
		$	3,628,976
	(1)         Refinance of prior note
	(2)         Includes mandatory conversion at the time of an initial public offering at a conversion price equal to 80% of the initial public offering price.
	(3)         This is a related party loan from Dr. Niihara, an officer and director of the Company.

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	3 Months Ended		12 Months Ended	3 Months Ended	0 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2009	Sep. 30, 2013	Sep. 11, 2013	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
			Number
Advertising Costs	$19,263	$67,147
Shares of CellSeed held as marketable securities	48,550
CellSeed, shares originally purchased (in shares)	147,100
CellSeed Investment, in Yen			100,028,000
CellSeed Investment, in Dollars			1,109,819
CellSeed Investment, in Yen per share			$680
CellSeed Investment, closing price in Yen	$688						$1,027
Available for sale securities, CellSeed stock (in shares)		9,300
CellSeed stock pledged against note		39,250
Potentially dilutive securities outstanding	12,838,502	14,254,868
Stock price	$4.90						$4.90
Additional Paid-In Capital [Member]
Issuance of stock and warrant units issued for cash				62,000
Private Placement - Warrants [Member]
Issuance of stock and warrant units issued for cash, shares					3,320,501
Stock price					$2.50
Transaction costs of issuance of warrants				619,000
Fair value adjustment of warrants		260,000		-29,000		-63,000	290,000	-92,000
Fair value of warrant liability				652,000	681,000	589,000	879,000	589,000
Number of shares upon conversion of warrant					1
Issuance of common stock purchase warrants issued for services - broker, shares					300,000
2011 Convertible notes payable [Member]
Convertible notes payable, Carrying Amount	$500,000						$500,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies Details
Raw materials and components		$43,700
Work-in-process	73,130	27,665
Finished goods	194,759	179,048
Total	$267,888	$250,413

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Liability Classified Warrants - Stock Purchase Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$3,206,000	$6,517,000
Fair value at issuance date		3,523,000
Settlement of liability associated with warrants exercised		-1,752,744
Reclassification to warrant derivative liabilities		-7,068,000
Reduction of the warrants exercised to intrinsic value included in the statement of comprehensive loss		-1,770,256
Change in fair value included in the statement of comprehensive loss	-186,000	3,757,000
Balance, end of period	3,020,000	3,206,000
Warrant Derivative Liabilities - Stock Purchase Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	6,520,000
Reclassification from liability classified warrants		7,068,000
Change in fair value included in the statement of comprehensive loss	-382,000	-548,000
Balance, end of period	$6,138,000	$6,520,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) (USD $)	0 Months Ended			3 Months Ended	12 Months Ended
	Sep. 11, 2014	Jun. 10, 2014	Sep. 11, 2013	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock price				$4.90	$4.90
Risk Free Interest Rate				1.57%	1.66%
Expected volatility (peer group)				67.30%	70.10%
Expected life				5 years	5 years
Balance, end of period:
Liability classified warrants				$3,020,000	$3,206,000
Warrant derivative liabilities				6,138,000	6,520,000
Warrants [Member]
Stock price	$5.10	$5.10	$3.60	$4.90	$4.90	$3.60
Risk Free Interest Rate	1.43%	1.32%	1.72%	1.00%	1.38%	1.75%
Expected volatility (peer group)	69.50%	68.20%	72.40%	66.40%	71.50%	63.20%
Expected life	3 years 11 months 7 days	4 years 2 months 24 days	5 years	3 years 5 months 7 days	3 years 7 months	4 years 7 months 6 days
Number outstanding	3,320,501	3,320,501	3,320,501	3,320,501	3,320,501	3,320,501
Balance, end of period:
Liability classified warrants	3,479,000	10,679,000	7,541,000	3,020,000	3,206,000	6,517,000
Warrant derivative liabilities	$7,068,000			$6,138,000	$6,520,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Minimum [Member]
Conversion rate (in dollars per share)	$3.05
Maximum [Member]
Conversion rate (in dollars per share)	$3.60
2015 Convertible notes payable - related party [Member]
Term of Loans	Due on demand ~ 2 years
Interest rate range	10.00%
Original Loan Principal Amount	$1,578,452
Beneficial Conversion Discount Amount	835,204
Warrants	110,417
Description of strike price	4.9
Warrant FMV Discount Amount	220,071
2015 Convertible notes payable - related party [Member] | Minimum [Member]
Conversion rate (in dollars per share)	$3.50
Effective Interest Rate Including Discounts	46.00%
2015 Convertible notes payable - related party [Member] | Maximum [Member]
Conversion rate (in dollars per share)	$3.60
Effective Interest Rate Including Discounts	109.00%
2014 Convertible notes payable - related party [Member]
Term of Loans	6 mo. ~ 2B years
Interest rate range	10.00%
Original Loan Principal Amount	3,096,266
Beneficial Conversion Discount Amount	1,392,387
Warrants	50,000
Description of strike price	3.5
Warrant FMV Discount Amount	126,732
2014 Convertible notes payable - related party [Member] | Minimum [Member]
Conversion rate (in dollars per share)	$3.05
Effective Interest Rate Including Discounts	28.00%
2014 Convertible notes payable - related party [Member] | Maximum [Member]
Conversion rate (in dollars per share)	$3.60
Effective Interest Rate Including Discounts	100.00%
Notes payable and convertible notes payable - related party [Member]
Original Loan Principal Amount	4,674,718
Conversion rate (in dollars per share)
Beneficial Conversion Discount Amount	2,227,591
Warrants	160,417
Warrant FMV Discount Amount	$346,803

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property And Equipment Details Narrative
Depreciation Expense	$5,523	$4,137

PROPERTY_AND_EQUIPMENT_Details1

PROPERTY AND EQUIPMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property and equipment
Property and equipment, gross	$267,095	$265,463
Less: accumulated depreciation	-198,652	-193,072
Property and equipment, net	68,443	72,391
Equipment [Member]
Property and equipment
Property and equipment, gross	161,712	160,201
Leasehold Improvements [Member]
Property and equipment
Property and equipment, gross	30,669	30,579
Furniture and Fixtures [Member]
Property and equipment
Property and equipment, gross	$74,714	$74,683

INTANGIBLE_ASSETS_Details_Narr

INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Intangible Assets Details Narrative
Amortization expense	$53,571	$53,572

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Intangible Assets Details
License fees and patent filing costs	$2,250,000	$2,250,000
Less: accumulated amortization	-1,410,714	-1,357,143
Total	$839,286	$892,857

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Year ending December 31
2015	$160,715
2016	214,286
2017	214,286
2018	214,286
2019	35,713
Total	$839,286	$892,857

ACCOUNTS_PAYABLE_AND_ACCRUED_E2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accounts Payable And Accrued Expenses Details
Clinical trial management expenses	$202,797	$266,537
Legal expenses	191,657	176,691
Other vendors	1,357,408	774,444
Subtotal	1,751,862	1,217,672
Accrued interest payable, related parties	134,380	110,200
Accrued interest payable	793,014	761,682
Accrued expenses	256,556	220,200
Deferred salary	291,666	291,666
Total accounts payable and accrued expenses	$3,227,478	$2,601,420

NOTES_PAYABLE_Details_Narrativ

NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Average stated interest rate	10.00%	10.00%
Average effective interest rate	21.00%		23.00%
Description of debt conversion	Certain notes with a $7.00 stated conversion price in the second year of their two year term are subject to automatic conversion into shares of our common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering.
Minimum [Member]
Conversion price	3.05
Maximum [Member]
Conversion price	3.6
Warrants [Member]
Simplified method	Black-Scholes-Merton option pricing model

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
	Number	Number
Principal Outstanding	$13,079,152	$11,985,917
Discount Amount	1,584,827	868,558
Total Carrying Amount	11,494,325	11,117,359
Shares Underlying Principal	2,470,128	2,415,613
Convertible notes payable, Current	3,138,015	3,456,959
Convertible notes payable, Non Current	3,635,761	3,651,555
Convertible notes payable related parties, Current	373,000	373,000
Convertible notes payable related parties, Non Current	373,000	373,000
Notes payable, Current	2,957,350	1,643,615
Notes payable, Non Current		833,335
Notes payable related parties, Current	1,190,199	825,562
Notes payable related parties, Non Current		133,333
Minimum [Member]
Conversion price	$3.05
Maximum [Member]
Conversion price	$3.60
2010 Convertible notes payable [Member]
Interest rate range, Minimum	0.00%	0.00%
Interest rate range, Maximum	6.00%	6.00%
Term of Notes	5B years	5B years
Conversion price	$3.05	$3.05
Principal Outstanding	74,000	74,000
Discount Amount	1,997	3,195
Convertible notes payable, Carrying Amount	72,003	70,805
Shares Underlying Principal	24,248	24,248
2011 Convertible notes payable [Member]
Interest rate	10.00%	10.00%
Term of Notes	5B years	5B years
Conversion price	$3.05	$3.05
Principal Outstanding	500,000	500,000
Discount Amount
Convertible notes payable, Carrying Amount	500,000	500,000
Shares Underlying Principal	163,809	163,809
2013 Convertible notes payable [Member]
Interest rate	10.00%	10.00%
Term of Notes	2B years	2B years
Principal Outstanding	1,841,187	2,463,299
Discount Amount	6,889	18,750
Convertible notes payable, Carrying Amount	1,834,298	2,444,549
Shares Underlying Principal	631,094	834,667
2013 Convertible notes payable [Member] | Minimum [Member]
Conversion price		$3.30
2013 Convertible notes payable [Member] | Maximum [Member]
Conversion price		$3.60
2014 Convertible notes payable [Member]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	4,164,963	4,939,773
Discount Amount	725,073	846,613
Convertible notes payable, Carrying Amount	3,439,890	4,093,160
Shares Underlying Principal	1,016,475	1,241,241
2014 Convertible notes payable [Member] | Minimum [Member]
Conversion price		$3.05
2014 Convertible notes payable [Member] | Maximum [Member]
Conversion price		$7
2015 Convertible notes payable [Member]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	1,778,453
Discount Amount	850,868
Convertible notes payable, Carrying Amount	927,585
Shares Underlying Principal	479,363
2015 Convertible notes payable [Member] | Minimum [Member]
Conversion price		$3.50
2015 Convertible notes payable [Member] | Maximum [Member]
Conversion price		$7
2012 Convertible notes payable - related party [Member]
Interest rate	10.00%	10.00%
Term of Notes	Due on demand	Due on demand
Conversion price	$3.30	$3.30
Principal Outstanding	373,000	373,000
Discount Amount
Convertible notes payable related parties, Carrying Amount	373,000	373,000
Shares Underlying Principal	124,248	121,461
2014 Convertible notes payable - related party [Member]
Interest rate	10.00%	10.00%
Term of Notes		2B years
Conversion price	$7	$7
Principal Outstanding	200,000	200,000
Discount Amount
Convertible notes payable related parties, Carrying Amount	200,000	200,000
Shares Underlying Principal		30,187
2013 Notes payable [Member]
Interest rate range, Minimum	2.00%	2.00%
Interest rate range, Maximum	10.00%	10.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	1,040,000	1,030,000
Discount Amount
Notes payable, Carrying Amount	1,040,000	1,030,000
Shares Underlying Principal
2014 Notes payable [Member]
Interest rate	11.00%	11.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	1,446,950	1,446,950
Discount Amount
Notes payable, Carrying Amount	1,446,950	1,446,950
Shares Underlying Principal
2015 Notes payable [Member]
Interest rate	11.00%	11.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	470,400
Discount Amount
Notes payable, Carrying Amount	470,400
Shares Underlying Principal
2012 Notes payable - related party [Member]
Interest rate range, Minimum	8.00%	8.00%
Interest rate range, Maximum	10.00%	10.00%
Term of Notes	Due on demand	Due on demand
Principal Outstanding	656,730	656,730
Discount Amount
Notes payable related parties, Carrying Amount	656,730	656,730
Shares Underlying Principal
2013 Notes payable - related party [Member]
Interest rate	8.00%	8.00%
Term of Notes	Due on demand	Due on demand
Principal Outstanding	50,000	50,000
Discount Amount
Notes payable related parties, Carrying Amount	50,000	50,000
Shares Underlying Principal
2014 Notes payable - related party [Member]
Interest rate	11.00%	11.00%
Term of Notes		Due on demand ~ 2B years
Principal Outstanding	240,308	252,165
Discount Amount
Notes payable related parties, Carrying Amount	240,308	252,165
Shares Underlying Principal
2015 Notes payable - related party [Member]
Interest rate range, Minimum	10.00%	10.00%
Interest rate range, Maximum	11.00%	11.00%
Term of Notes	Due on demand ~ 2B years	Due on demand ~ 2B years
Principal Outstanding	243,161
Discount Amount
Notes payable related parties, Carrying Amount	243,161
Shares Underlying Principal
2015 Convertible notes payable - related party [Member]
Term of Notes	2B years
Shares Underlying Principal	30,891
2014 Notes payable - related party [Member]
Term of Notes	Due on demand ~ 2B years
Shares Underlying Principal
Convertible notes payable [Member]
Principal Outstanding	8,358,603	7,977,072
Discount Amount	1,584,827	868,558
Convertible notes payable, Carrying Amount	6,773,776	7,108,514
Shares Underlying Principal	2,314,989	2,263,965
Principal Outstanding, Current	3,776,083	3,478,904
Principal Outstanding, Non Current	4,582,520	4,498,168
Discount Amount Current	638,068	21,945
Discount Amount Non Current	946,759	846,613
Convertible notes payable, Current	3,138,015	3,456,959
Convertible notes payable, Non Current	3,635,761	3,651,555
Shares Underlying Principal Current	1,221,962	1,156,050
Shares Underlying Principal Non Current	1,093,027	1,107,915
Convertible notes payable - related party [Member]
Conversion price
Principal Outstanding	573,000	573,000
Discount Amount
Convertible notes payable related parties, Carrying Amount	573,000	573,000
Total Carrying Amount	373,000	373,000
Shares Underlying Principal	124,248	151,648
Principal Outstanding, Current	373,000	373,000
Principal Outstanding, Non Current	200,000	200,000
Discount Amount Current
Discount Amount Non Current
Convertible notes payable related parties, Current	373,000	373,000
Convertible notes payable related parties, Non Current	200,000	200,000
Shares Underlying Principal Current	124,248	121,461
Shares Underlying Principal Non Current	30,891	30,187
Notes Payable [Member]
Principal Outstanding	2,957,350	2,476,950
Discount Amount
Notes payable, Carrying Amount	2,957,350	2,476,950
Shares Underlying Principal
Principal Outstanding, Current	2,957,350	1,643,615
Principal Outstanding, Non Current		833,335
Discount Amount Current
Discount Amount Non Current
Notes payable, Current	2,957,350	1,643,615
Notes payable, Non Current		833,335
Shares Underlying Principal Current
Shares Underlying Principal Non Current
Notes payable - related party [Member]
Conversion price
Principal Outstanding	1,190,199	958,895
Discount Amount
Notes payable related parties, Carrying Amount	1,190,199	958,895
Total Carrying Amount	1,190,199	825,562
Shares Underlying Principal
Principal Outstanding, Current	1,190,199	825,562
Principal Outstanding, Non Current		133,333
Discount Amount Current
Discount Amount Non Current
Notes payable related parties, Current	1,190,199	825,562
Notes payable related parties, Non Current		$133,333
Shares Underlying Principal Current
Shares Underlying Principal Non Current

NOTES_PAYABLE_Details_1

NOTES PAYABLE (Details 1) (USD $)	Mar. 31, 2015
Contractual principal payments due on loans and notes payable for the year ending
2015	$6,466,386
2016	5,787,192
2017	825,574
Total	$13,079,152

NOTES_PAYABLE_Details_2

NOTES PAYABLE (Details 2) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Fair value of options and warrants
Stock Price	$4.90	$4.90
Exercise Price	$4.90	$3.50
Term	5 years	5 years
Risk-free interest rate	1.57%	1.66%
Expected volatility	67.30%	70.10%

STOCKHOLDERS_EQUITY_DEFICIT_De

STOCKHOLDERS' EQUITY (DEFICIT) (Details Narrative) (USD $)	3 Months Ended		12 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jun. 10, 2014	Jun. 10, 2015	Sep. 11, 2013	Dec. 31, 2013	Sep. 11, 2014
Share-based compensation	$1,641,244	$1,607,708
Share price (in dollars per share)	$4.90		4.9
Warrant derivative liabilities	6,138,000		6,520,000
Liability classified warrants	3,020,000		3,206,000
Registrable Securities [Member]
Numbers of units issued	4,115,966
Share price (in dollars per share)					$5.90
Number of cashless units warrants outstanding	905,099				1,350,712
Numbers of securities purchased	3,320,501
2011 Stock Incentive Option Plan [Member]
Options outstanding	5,669,000		5,669,000				4,504,000
Additional options granted			1,180,000
2011 Stock Incentive Option Plan [Member] | Stock Options [Member]
Options outstanding	5,669,000
Weighted average grant-date fair value of options		$2.19
Weighted average grant-date fair value of common shares options		$3.60
Share-based compensation	1,600,000	1,600,000
Total unrecognized compensation cost	4,500,000
Unrecognized compensation cost weighted average remaining period	1 year 4 months 7 days
Method used	Black-Scholes-Merton Option pricing model
2011 Stock Incentive Option Plan [Member] | Stock Options [Member] | Directors, Employees And Consultants [Member]
Granted	840,000
Additional options granted	340,000
Fair value of options granted	3,000,000
Prior 2011 Stock Incentive Plan [Member]
Options outstanding	11,795		11,795
Additional options granted
Prior 2011 Stock Incentive Plan [Member] | Stock Options [Member]
Fair value of options granted	11,795
Private Placement [Member]
Number of cashless units warrants outstanding	2,225,036			2,225,036				2,225,036
Warrant derivative liabilities	5,310,000			1,800,000				7,068,000
Numbers of securities purchased				1,095,465
Excrcise price (in dollars per share)				3.5
Number of replacement warrants				1,095,465
Method used				Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model.
Private Placement [Member] | Registrable Securities [Member]
Share price (in dollars per share)					$4.90
Increase number of cashless units warrants					948,715
Number of cashless units warrants outstanding					3,320,501
Warrants [Member]
Granted	110,417		1,145,465
Share price (in dollars per share)	$4.90		4.9	$5.10		$3.60	3.6	$5.10
Warrant derivative liabilities	6,138,000		6,520,000					7,068,000
Numbers of securities purchased	94,762
Liability classified warrants	3,020,000		3,206,000	10,679,000		7,541,000	6,517,000	3,479,000
Warrants [Member] | Maximum [Member]
Excrcise price (in dollars per share)	3.05
Warrants [Member] | Minimum [Member]
Excrcise price (in dollars per share)	1
Warrants [Member] | 2014 Convertible notes payable [Member]
Numbers of units issued	110,417
Share price (in dollars per share)	$4.90
Private Placement - Warrants [Member]
Share price (in dollars per share)						$2.50
Description of private placement units						Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock.
Purchase price of units						$7,551,253
Common stock exercise price						$3.50

STOCKHOLDERS_EQUITY_DEFICIT_De1

STOCKHOLDERS' EQUITY (DEFICIT) (Details) (Warrants [Member])	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrants [Member]
Warrants outstanding summary
Warrants outstanding, beginning of period	5,101,450	6,279,296
Granted	110,417	1,145,465
Exercised	-94,762	-1,254,621
Cancelled, forfeited and expired	-429,526	-1,068,690
Warrants outstanding, end of period	4,687,579	5,101,450

STOCKHOLDERS_EQUITY_DEFICIT_De2

STOCKHOLDERS' EQUITY (DEFICIT) (Details 1)	3 Months Ended
	Mar. 31, 2015
Warrants Issued in 2012 - Exercise Price $2.50 [Member]
Year Issued	2012
Weighted Average Exercise Price	2.5
Outstanding
Number of Warrants	1,000,000
Weighted Average Remaining Contractual Life (Years)	4 months 6 days
Exercisable
Total	1,000,000
Warrants Issued in 2012 - Exercise Price $3.05 [Member]
Year Issued	2012
Weighted Average Exercise Price	3.05
Outstanding
Number of Warrants	156,661
Weighted Average Remaining Contractual Life (Years)	6 months
Exercisable
Total	156,661
Warrants Issued in 2012 [Member]
Outstanding
Number of Warrants	1,156,661
Exercisable
Total	1,156,661
Warrants Issued in 2013 - Exercise Price $3.30 [Member]
Year Issued	2013
Weighted Average Exercise Price	3.3
Outstanding
Number of Warrants	50,000
Weighted Average Remaining Contractual Life (Years)	3 years 29 days
Exercisable
Total	50,000
Warrants Issued in 2013 - Exercise Price $3.50 [Member]
Year Issued	2013
Weighted Average Exercise Price	3.5
Outstanding
Number of Warrants	2,225,036
Weighted Average Remaining Contractual Life (Years)	3 years 4 months 12 days
Exercisable
Total	2,225,036
Warrants Issued in 2013 [Member]
Outstanding
Number of Warrants	2,275,036
Exercisable
Total	2,275,036
Warrants Issued in 2014 - Exercise Price $3.50 [Member]
Year Issued	2014
Weighted Average Exercise Price	3.5
Outstanding
Number of Warrants	1,145,465
Weighted Average Remaining Contractual Life (Years)	3 years 5 months 23 days
Exercisable
Total	1,145,465
Warrants Issued in 2014 [Member]
Outstanding
Number of Warrants	1,145,465
Exercisable
Total	1,145,465
Warrants [Member]
Year Issued	2015
Weighted Average Exercise Price	4.9
Outstanding
Number of Warrants	110,417
Weighted Average Remaining Contractual Life (Years)	4 years 11 months 7 days
Exercisable
Total	110,417
Warrants Issued in 2015 [Member]
Outstanding
Number of Warrants	4,687,579
Exercisable
Total	4,687,579

STOCKHOLDERS_EQUITY_DEFICIT_De3

STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Prior 2011 Stock Incentive Plan [Member]
Number of options:
Number of Options outstanding, beginning	11,795
Number of Options granted
Number of Options exercised
Number of Options forfeited
Number of Options outstanding, ending	11,795
Number of Options exercisable	11,795
Options available for future grant
Weighted Average Exercise Price:
Weighted Average Exercise Price of Options outstanding, beginning	$3.05
Weighted Average Exercise Price of Options granted
Weighted Average Exercise Price of Options exercised
Weighted Average Exercise Price of Options forfeited
Weighted Average Exercise Price of Options outstanding, ending	$3.05
Weighted Average Exercise Price of Options exercisable	$3.05
2011 Stock Incentive Option Plan [Member]
Number of options:
Number of Options outstanding, beginning	5,669,000	4,504,000
Number of Options granted		1,180,000
Number of Options exercised
Number of Options forfeited		-15,000
Number of Options outstanding, ending	5,669,000	5,669,000
Number of Options exercisable	3,461,917	2,855,251
Options available for future grant	3,331,000	3,331,000
Weighted Average Exercise Price:
Weighted Average Exercise Price of Options outstanding, beginning	$3.68	$3.58
Weighted Average Exercise Price of Options granted		$4.06
Weighted Average Exercise Price of Options exercised
Weighted Average Exercise Price of Options forfeited		$3.60
Weighted Average Exercise Price of Options outstanding, ending	$3.68	$3.68
Weighted Average Exercise Price of Options exercisable	$3.57	$3.55

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Commitments And Contingencies Details Narrative
Monthly commercialization management fee	$5,000
Rent expense	$118,192	$46,094

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Mar. 31, 2015
Future minimum lease payments
2015	$308,601
2016	490,140
2017	467,811
2018	481,845
2019	123,766
Total Future Minimum Lease Payments Due	$1,872,163

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative)	0 Months Ended
	Jun. 27, 2013
Related Party Transactions Details Narrative
Number of shares cancelled	2,504,249

RELATED_PARTY_TRANSACTIONS_Det1

RELATED PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
	Number		Number
Principal Amount Outstanding	$11,494,325		$11,117,359
Shares Underlying Principal	2,470,128		2,415,613
Less discount	-1,584,827		-868,558
Total	13,079,152
Hope Hospice [Member]
Annual Interest Rate	8.00%	[1]	8.00%	[1]
Date of Loan	17-Jan-12		17-Jan-12	[1]
Term of Loan	Due on demand		Due on demand	[1]
Principal Amount Outstanding	200,000	[1]	200,000	[1]
Highest Principal Outstanding	200,000	[1]	200,000	[1]
Amount of Principal Repaid				[1]
Amount of Interest Paid			16,000	[1]
Debt conversion price		[1]		[1]
Shares Underlying Principal
Hope Hospice [Member]
Annual Interest Rate	8.00%	[1]	8.00%	[1]
Date of Loan	14-Jun-12	[1]	14-Jun-12	[1]
Term of Loan	Due on demand	[1]	Due on demand	[1]
Principal Amount Outstanding	200,000	[1]	200,000	[1]
Highest Principal Outstanding	200,000	[1]	200,000	[1]
Amount of Principal Repaid		[1]		[1]
Amount of Interest Paid		[1]	20,000	[1]
Debt conversion price		[1]		[1]
Shares Underlying Principal		[1]
Hope Hospice [Member]
Annual Interest Rate	8.00%	[1]	8.00%	[1]
Date of Loan	21-Jun-12	[1]	21-Jun-12	[1]
Term of Loan	Due on demand	[1]	Due on demand	[1]
Principal Amount Outstanding	100,000	[1]	100,000	[1]
Highest Principal Outstanding	100,000	[1]	100,000	[1]
Amount of Principal Repaid		[1]		[1]
Amount of Interest Paid		[1]	10,000	[1]
Debt conversion price		[1]		[1]
Shares Underlying Principal		[1]
Yutaka Niihara [Member]
Annual Interest Rate	10.00%	[2],[3]	1.00%	[2],[3]
Date of Loan	5-Dec-12	[2],[3]	5-Dec-12	[2],[3]
Term of Loan	Due on demand	[2],[3]	Due on demand	[2],[3]
Principal Amount Outstanding	156,730	[2],[3]	156,730	[2],[3]
Highest Principal Outstanding	1,213,700	[2],[3]	1,213,700	[2],[3]
Amount of Principal Repaid	1,056,970	[2],[3]	1,056,970	[2],[3]
Amount of Interest Paid		[2],[3]	60,851	[2],[3]
Debt conversion price		[2],[3]		[2],[3]
Shares Underlying Principal		[2],[3]
Hope Hospice [Member]
Annual Interest Rate	8.00%	[1]	8.00%	[1]
Date of Loan	11-Feb-13	[1]	11-Feb-13	[1]
Term of Loan	Due on demand	[1]	Due on demand	[1]
Principal Amount Outstanding	50,000	[1]	50,000	[1]
Highest Principal Outstanding	50,000	[1]	50,000	[1]
Amount of Principal Repaid		[1]		[1]
Amount of Interest Paid		[1]	4,000	[1]
Debt conversion price		[1]		[1]
Shares Underlying Principal		[1]
Lan T. Tran [Member]
Annual Interest Rate	11.00%	[2]	11.00%	[2]
Date of Loan	10-Feb-14	[2]	10-Feb-14	[2]
Term of Loan	2 years	[2],[4]	2 years	[2],[4]
Principal Amount Outstanding	106,976	[2]	106,976	[2]
Highest Principal Outstanding	106,976	[2]	106,976	[2]
Amount of Principal Repaid		[2]		[2]
Amount of Interest Paid		[2]		[2]
Debt conversion price		[2]		[2]
Shares Underlying Principal		[2]
Cuc T. Tran [Member]
Annual Interest Rate	11.00%	[5]	11.00%	[5]
Date of Loan	5-Mar-15	[5]	5-Mar-14	[5]
Term of Loan	1B year	[5]	1 year	[5]
Principal Amount Outstanding	13,161	[5]	11,856	[5]
Highest Principal Outstanding	13,161	[5]	11,856	[5]
Amount of Principal Repaid		[5]		[5]
Amount of Interest Paid		[5]		[5]
Debt conversion price		[5]		[5]
Shares Underlying Principal		[5]
Notes payable - related party [Member]
Principal Amount Outstanding	1,190,199		825,562
Highest Principal Outstanding	2,247,170		1,882,532
Amount of Principal Repaid	1,056,970		1,056,970
Amount of Interest Paid			110,851
Debt conversion price
Shares Underlying Principal
Less discount
Yasushi Nagasaki [Member]
Annual Interest Rate	10.00%	[2]	10.00%	[2]
Date of Loan	29-Jun-12	[2]	29-Jun-12	[2]
Term of Loan	Due on demand	[2]	Due on demand	[2]
Principal Amount Outstanding	373,000	[2]	373,000	[2]
Highest Principal Outstanding	388,800	[2]	388,800	[2]
Amount of Principal Repaid	15,800	[2]	15,800	[2]
Amount of Interest Paid		[2]	67,680	[2]
Debt conversion price	$3.30	[2]	$3.30	[2]
Shares Underlying Principal	124,248	[2]	121,461	[2]
Convertible notes payable - related party [Member]
Principal Amount Outstanding	373,000		373,000
Highest Principal Outstanding	388,800		388,800
Amount of Principal Repaid	15,800		15,800
Amount of Interest Paid			67,680
Debt conversion price
Shares Underlying Principal	124,248		151,648
Less discount
Hideki and Eiko Uehara [Member]
Annual Interest Rate			11.00%	[5]
Date of Loan			15-Feb-14	[5]
Term of Loan			2 years	[5]
Principal Amount Outstanding			133,333	[5]
Highest Principal Outstanding			133,333	[5]
Amount of Principal Repaid				[5]
Amount of Interest Paid			14,697	[5]
Debt conversion price				[5]
Long-term promissory note payable to related parties [Member]
Principal Amount Outstanding			133,333
Highest Principal Outstanding			133,333
Amount of Principal Repaid
Amount of Interest Paid			14,697
Debt conversion price
Phillip M. Satow [Member]
Annual Interest Rate	10.00%	[3]	10.00%	[3]
Date of Loan	6-Jun-14	[3]	6-Jun-14	[3]
Term of Loan	2B years	[3]	2 years	[3]
Principal Amount Outstanding	100,000	[3]	100,000	[3]
Highest Principal Outstanding	100,000	[3]	100,000	[3]
Amount of Principal Repaid		[3]		[3]
Amount of Interest Paid		[3]		[3]
Debt conversion price	$7	[3]	$7	[3]
Shares Underlying Principal	15,455	[3]
Richard S. Pechter [Member]
Annual Interest Rate	10.00%	[5]	10.00%	[3]
Date of Loan	11-Jun-14	[5]	11-Jun-14	[5]
Term of Loan	2B years	[5]	2 years	[5]
Principal Amount Outstanding	100,000	[5]	100,000	[3]
Highest Principal Outstanding	100,000	[5]	100,000	[3]
Amount of Principal Repaid		[5]		[5]
Amount of Interest Paid		[5]		[5]
Debt conversion price	$7	[5]	$7	[3]
Shares Underlying Principal	15,436	[5]
Long-term convertible notes payable - related party [Member]
Principal Amount Outstanding	200,000		200,000
Highest Principal Outstanding	200,000		200,000
Amount of Principal Repaid
Amount of Interest Paid
Debt conversion price
Shares Underlying Principal	30,891
Notes payable and convertible notes payable - related party [Member]
Principal Amount Outstanding	1,763,199		1,531,895
Highest Principal Outstanding	2,835,970		2,604,665
Amount of Principal Repaid	1,072,770		1,072,770
Amount of Interest Paid			193,228
Debt conversion price
Shares Underlying Principal	155,139
Hideki AndEiko Uehara [Member]
Annual Interest Rate	11.00%	[5]
Date of Loan	15-Feb-14	[5]
Term of Loan	2 years	[5]
Principal Amount Outstanding	133,333	[5]
Highest Principal Outstanding	133,333	[5]
Amount of Principal Repaid		[5]
Amount of Interest Paid		[5]
Debt conversion price		[5]
Shares Underlying Principal		[5]
Hope Hospice [Member]
Annual Interest Rate	10.00%	[1]
Date of Loan	7-Jan-15	[1]
Term of Loan	2 years	[1],[4]
Principal Amount Outstanding	100,000	[1]
Highest Principal Outstanding	100,000	[1]
Amount of Principal Repaid		[1]
Amount of Interest Paid		[1]
Debt conversion price		[1]
Shares Underlying Principal		[1]
James Lee [Member]
Annual Interest Rate	10.00%	[5]
Date of Loan	26-Jan-15	[5]
Term of Loan	2 years	[4],[5]
Principal Amount Outstanding	50,000	[5]
Highest Principal Outstanding	50,000	[5]
Amount of Principal Repaid		[5]
Amount of Interest Paid		[5]
Debt conversion price		[5]
Shares Underlying Principal		[5]
Yutaka Niihara [Member]
Annual Interest Rate	10.00%	[2],[3]
Date of Loan	29-Jan-15	[2],[3]
Term of Loan	2 years	[2],[3],[4]
Principal Amount Outstanding	20,000	[2],[3]
Highest Principal Outstanding	20,000	[2],[3]
Amount of Principal Repaid		[2],[3]
Amount of Interest Paid		[2],[3]
Debt conversion price		[2],[3]
Shares Underlying Principal		[2],[3]
Hope Hospice [Member]
Annual Interest Rate	10.00%	[1]
Date of Loan	29-Jan-15	[1]
Term of Loan	2 years	[1],[4]
Principal Amount Outstanding	30,000	[1]
Highest Principal Outstanding	30,000	[1]
Amount of Principal Repaid		[1]
Amount of Interest Paid		[1]
Debt conversion price		[1]
Shares Underlying Principal		[1]
Lan T. Tran [Member]
Annual Interest Rate	10.00%	[2]
Date of Loan	9-Feb-15	[2]
Term of Loan	2B years	[2],[4]
Principal Amount Outstanding	10,000	[2]
Highest Principal Outstanding	10,000	[2]
Amount of Principal Repaid		[2]
Amount of Interest Paid		[2]
Debt conversion price		[2]
Shares Underlying Principal		[2]
Charles Stark [Member]
Annual Interest Rate	10.00%	[2]
Date of Loan	10-Feb-15	[2]
Term of Loan	2 years	[2],[4]
Principal Amount Outstanding	10,000	[2]
Highest Principal Outstanding	10,000	[2]
Amount of Principal Repaid		[2]
Amount of Interest Paid		[2]
Debt conversion price		[2]
Shares Underlying Principal		[2]
IRA Service Trust Co. FBO Peter B. Ludlum [Member]
Annual Interest Rate	10.00%	[2]
Date of Loan	20-Feb-15	[2]
Term of Loan	2 years	[2],[4]
Principal Amount Outstanding	10,000	[2]
Highest Principal Outstanding	10,000	[2]
Amount of Principal Repaid		[2]
Amount of Interest Paid		[2]
Debt conversion price		[2]
Shares Underlying Principal		[2]
[1]	Dr. Niihara is the CEO of Hope Hospice.
[2]	Officer
[3]	Director
[4]	Due on Demand
[5]	Family of Officer/Director

GEOGRAPHIC_INFORMATION_Details

GEOGRAPHIC INFORMATION (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Japan [Member]
Company revenue earned from countries outside of the U.S.
Revenue	$42,743	$41,778
Percentage of revenue (in percent)	44.00%	43.00%
Taiwan [Member]
Company revenue earned from countries outside of the U.S.
Revenue	$42,613	$27,730
Percentage of revenue (in percent)	44.00%	28.00%

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Principal Outstanding	$13,079,152		$11,985,917
Subsequent Event [Member]
Principal Outstanding	3,628,976
Subsequent Event [Member] | Convertible Note [Member]
Principal Outstanding	462,993	[1]
Annual Interest Rate (in percent)	10.00%	[1]
Term of Notes	2 years	[1]
Conversion price	$3.60	[1]
Subsequent Event [Member] | Convertible Note [Member]
Principal Outstanding	272,640	[1]
Annual Interest Rate (in percent)	10.00%	[1]
Term of Notes	2 years	[1]
Conversion price	$3.50	[1]
Subsequent Event [Member] | Convertible Notes [Member]
Principal Outstanding	893,343	[2]
Annual Interest Rate (in percent)	10.00%	[2]
Term of Notes	2 years	[2]
Conversion price	$4.50	[2]
Subsequent Event [Member] | Promissory Note [Member]
Principal Outstanding	500,000	[3]
Annual Interest Rate (in percent)	10.00%	[3]
Term of Notes	On demand up to 2 years	[3]
Subsequent Event [Member] | Promissory Notes Related Party [Member]
Principal Outstanding	$1,500,000
Annual Interest Rate (in percent)	11.00%
Term of Notes	On demand up to 2 years
[1]	Refinance of prior note
[2]	Includes mandatory conversion at the time of an initial public offering at a conversion price equal to 80% of the initial public offering price.
[3]	This is a related party loan from Dr. Niihara, an officer and director of the Company.